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Vancomycin is an antibiotic administered intravenously for severe invasive infections and due to 
its low therapeutic index, therapeutic drug monitoring is recommended. Clinical staff at the Canterbury 
District Health Board (CDHB) have been monitoring serum concentrations and targeting a Cmin of 15-20 
mg/L. The 2020 guidelines from the Infectious Diseases Society of America (IDSA) recommend directly 
monitoring the AUC0-24h/MICBMD for Methicillin Resistant Staphylococcus Aureus due to: increased rates 
of target attainment, reduced overexposure and that this metric accounts for bacterial susceptibility 
compared to Cmin values. The value of AUC24 can be difficult to estimate, requiring several concentrations 
across a dose profile, using empirical estimates or specialised software. Clinical staff at the CDHB have 
access to a Bayesian forecasting software, TCIWorks with the Thomson et al. model implemented; to date 
there has been no evaluation of the accuracy of a limited sampling strategy combined with this solution. 
This research had three aims: 1) To determine whether a limited vancomycin sampling strategy (1-
2 samples per dosing interval, using Bayesian methods) can accurately predict the AUC0-24h at steady state 
(AUCss0-24h) of vancomycin in adults, 2) to determine whether accuracy in the AUCss0-24h predictions 
differs between obese and non-obese patients, and, 3) to investigate factors contributing to bias in the 
AUCss0-24h estimate. A simulation study was undertaken using demographic dosing data from patients 
administered vancomycin at the CDHB between 2016 and 2019 and nine sampling strategies where 1-2 
simulated samples were included in the Bayesian forecasting per course, varying the day of the sample(s). 
Values of mean prediction error (mg.h/L) and AUC of the sample strategy versus a simulated reference 
AUC (AUCssTest: 0-24h/AUCssRef: 0-24h) were calculated for each sample strategy and the latter was compared 
to a bioequivalence range recommended for low therapeutic index medications (0.900-1.111). To estimate 
the accuracy of each sampling strategy, the proportion of values of AUCssTest: 0-24h within 20% of the 
AUCssRef: -24h was calculated (P20). 
It was found that the sampling strategies were unable to estimate an unbiased result across the 
dataset; all strategies significantly underestimated the value of AUCssTest: 0-24h (mean prediction error: -
70.52 (95% CI -97.37, -43.68) to -59.08 (95% CI -77.13, -41.02)) and only one strategy met the 
bioequivalence criteria; using the Cmin for doses 2 and 3. Stratification by obesity status found bias in obese 
individuals but not non-obese individuals. This was corroborated by the multilinear regression model which 
found that BMI was a significant predictor of the prediction error (coefficient -4.50 (95% CI -7.06, -1.94); 
p < 0.001). 
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This research provided useful information that any of the strategies implemented could estimate 
AUCss0-24h in non-obese individuals with sufficient accuracy. Further research into strategies for obese 
individuals is required.  
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1 Introduction 
 Introduction to thesis 
Vancomycin is an antibiotic administered intravenously for severe invasive infections and due to 
its low therapeutic index, therapeutic drug monitoring is recommended. Clinical staff at the Canterbury 
District Health Board (CDHB) monitor vancomycin using Cmin concentrations; samples are initially taken 
prior to the fourth dose and doses adjusted to achieve a Cmin target a range of 15-20 mg/L. The most recent 
guidelines for vancomycin dosing and monitoring (1) recommend using the pharmacokinetic-
pharmacodynamic (PKPD) metric of the ratio of the area under the curve (for 24 hours) to the minimum 
inhibitory concentration (as determined by broth microdilution) – AUC24/MICBMD – with a target range of 
400-600. AUC24/MICBMD monitoring has been shown to: increase rates of target attainment, reduce harm 
from overexposure and account for bacterial variances in susceptibility when compared to using Cmin values 
(1). This target is recommended for Methicillin Resistant Staphylococcus Aureus infections but is often 
extended to other organisms due to a paucity of data, and, reducing inappropriate exposure is important 
regardless of the target organism. Calculation of AUC24 requires several drug concentrations across a dosing 
interval, the use of empirical estimates, or specialised software. Therefore, monitoring Cmin continues to be 
the most common monitoring approach in clinical practice. Clinical staff at the CDHB have access to a 
Bayesian forecasting software, TCIWorks, which incorporates a well-studied two compartment 
pharmacokinetic model for vancomycin (2). To date, there has been no investigation into the accuracy of 
using 1-2 samples per dosing interval and TCIWorks in estimating an individual’s AUC24. It is therefore 
unclear if measuring 1-2 samples per dosing interval as a means of estimating AUC24 is suitable for the 
therapeutic drug monitoring programme offered by the Department of Clinical Pharmacology.  
 Study aims 
The study has three aims; 1) To determine whether a limited vancomycin sampling strategy (1-2 
samples per dosing interval, using Bayesian methods) can accurately predict the AUC24 at steady state 
(AUCss0-24h) of vancomycin in adults, 2) to determine whether accuracy in the AUCss0-24h predictions 





 Dose optimisation of vancomycin: a review of the literature 
 Vancomycin 
Vancomycin is a glycopeptide antibiotic that has been in clinical use for more than 60 years (3). 
Vancomycin is used for treatment of invasive gram-positive bacteria. Specifically, it is recommended for 
penicillinase-producing Staphylococcus aureus (1, 4), methicillin-resistant Staphylococcus aureus (MRSA) 
(5) and is one of the few antibiotics able to treat coagulase-negative Staphylococcus species (6). Infections 
due to MRSA are associated with increased morbidity, mortality, and health care costs (7); estimates of 
mortality vary, but have been reported in excess of 20% of bacteraemia cases and may be higher in 
complicated infections such as endocarditis or osteomyelitis (8). As rates of MRSA are increasing in New 
Zealand (9), adequate dosing and monitoring are essential to ensure safety and efficacy and minimise the 
risk of resistance developing. 
 Physicochemical properties 
Vancomycin is a weak acid and when reconstituted with water it is a clear solution with a pH of 
2.8-4.5 (10). The free acid form of vancomycin has a molecular weight of 1449.3 Daltons (6, 11) while the 
hydrochloride salt is larger at 1485.7 Daltons (12). Vancomycin hydrochloride is insoluble in alcohol but 
is freely soluble in water up to 100 mg/mL (11, 13). 
 
Figure 1.1: Chemical structure of vancomycin (14) 
Vancomycin has several pKa values: pka1 = 2.6, pka2 = 7.2, pka3 = 8.6, pka4 = 9.6, pka5 = 10.5, 
pka6 = 11.7 (11); at physiological pH, vancomycin is ionized and also has a logP value of -3.1 (11), 





Vancomycin is not absorbed well via the oral route (6) with an oral bioavailability of less than 5%. 
Therefore, for systemic infections, vancomycin needs to be administered parenterally. 
 Distribution 
Vancomycin has a reported α-distribution phase of 30-60 minutes in patients with normal renal 
function (6). As vancomycin is a hydrophilic drug, the volume of distribution (Vd) approximates the 
extracellular fluid volume (15). A reported range of volume of distribution at steady state is 0.4-1 L/kg. 
While the absolute volume of distribution increases with body mass, it does not appear to increase 
proportionally. The proportional volume of distribution (in L/kg) appears to be lower in obese subjects 
compared to their non-obese counterparts (1), an estimate of 0.5 L/kg for obese adults has been suggested 
from more recent studies (1). Vancomycin is protein bound 10-50% (6) to IgA and albumin (16), although, 
the extent of protein binding can vary significantly between hospitalized patients due to individual 
physiological conditions (15). Despite this variability in protein binding, it is current practice to measure 
total rather than free vancomycin concentrations (4). 
Vancomycin penetrates most body spaces, except cerebrospinal fluid (6, 11). Tissue penetration in 
general is affected by inflammation which increases penetration (6). Vancomycin distributes into breastmilk 
post intravenous administration and readily crosses the placenta and distributes into the cord blood (11). 
 Elimination 
More than 80-90% of vancomycin is found unchanged in urine within 24 hours of intravenous 
administration with normal renal function (6, 17). Vancomycin is primarily excreted via glomerular 
filtration but is also secreted in the renal tubules (17); this could explain how the clearance approximately 
matches the glomerular filtration rate (18) despite binding to plasma proteins.. Vancomycin is also 
measurable in bile and stool post-administration (17) which indicates that extrarenal routes are involved, 
but to a lesser extent. Dosage adjustments are recommended in renal impairment, but not hepatic 
impairment due to the significance of renal clearance (17). It has been reported that vancomycin has a β-
elimination half-life of 6-12 hours in patients with normal renal function (6). 
 Mechanism of action 
Vancomycin binds with high affinity to precursor components of peptidoglycans, preventing its 
formation (19); therefore. vancomycin is only active against gram-positive organisms (20). Vancomycin 
appears to have a bactericidal time-dependent killing effect (1, 6, 21) as well as a moderately long  
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postantibiotic effect (22). The postantibiotic effect is affected by vancomycin concentrations; 
concentrations of 2-4 times the MIC increase the postantibiotic effect from 0.2 to 2 hours (6). 
 Safety 
Vancomycin is associated with nephrotoxicity (1). Early formulations of vancomycin were not pure 
(purity of about 70%) and were linked to the high rate of nephrotoxicity (1, 6). Nephrotoxicity is currently 
estimated to affect 5%-35% of vancomycin courses (23). It is more likely in the presence of other risk 
factors, including: obesity; deep visceral infections as well as concomitant nephrotoxic medication (e.g. 
contrast dye or other antibiotics); and vancomycin exposure (dose or duration) (23-26). 
The nephrotoxic effect of vancomycin can lead to an acute kidney injury (AKI) by the combination 
of oxidative stress on the proximal tubules (23, 27) and mitochondrial disfunction (23). Most episodes of 
vancomycin induced AKI occur between 4 and 17 days of therapy (1). While nephrotoxicity due to 
vancomycin it is typically reversible (18, 26) and rarely requires dialysis (26), many patients do not fully 
recover renal function after vancomycin-induced AKI (1). 
Vancomycin is administered by slow intravenous infusion (for example, 500 mg over 60 minutes) 
as a means of minimising the risk vancomycin infusion reactions (28, 29). This is a combination of fever, 
chills, and phlebitis along with tingling or flushing of the face, neck and torso. It is related to the rate of 
administration (>500 mg over ≤30 minutes) resulting in a histamine release (28). 
 Dose optimisation 
Clinical staff at the Canterbury District Health Board (CDHB) monitor vancomycin using pre-dose 
(Cmin) concentrations at steady state, targeting a range of 15-20 mg/L. Local guidelines recommend a 
loading dose based on actual body weight (up to a maximum of 3000 mg), with an initial maintenance dose 
between 375-2000 mg 12-hourly depending on renal function. Cmin concentrations are then recommended 
to be taken prior to the fourth dose. Adjustments to vancomycin courses are made on the proportional 
difference between the result obtained and the target range; either the dose or frequency of administration 
is adjusted so the Cmin is within the target range. These recommendations align with that from the 2009 
Infectious Diseases Society of America (IDSA) (28) which advocated for this metric and target range. The 
monitoring of vancomycin plasma concentrations to guide safe and effective dosing is recommended in all 
patients who are at a higher risk of nephrotoxicity (30): those with unstable renal function; those who are 
receiving courses >3 days (1); or who are clinically unstable. 
Despite the long-standing use of vancomycin for MRSA, the optimal monitoring method continues 
to be debated and examined (3). To date there are dozens of studies investigating monitoring strategies for 
vancomycin recommending specific metrics and target levels for efficacy and safety. These have 
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highlighted the importance of the host-pathogen interaction; the presence of biofilm, bacterial load and site 
of infection (3, 6). There have been very few human studies evaluating specific vancomycin metrics, and 
those that do tend to include small patient populations with varying infections (6). 
 Pharmacokinetic targets for safety and efficacy  
 Pre-dose (Cmin) concentrations 
Historically, pre-dose (Cmin) concentrations have long been recommended as the metric to monitor 
vancomycin. The original target range was recommended at 5-10 mg/L to minimise the risk of 
nephrotoxicity but has increased over time due to increased rates of bacterial resistance to 15-20 mg/L (28). 
Literature supports maintaining Cmin plasma concentrations >10 mg/L to prevent development of resistant 
S. aureus (1, 31) as resistance can occur with prolonged exposure to low plasma concentrations (32). 
Several groups have investigated this more aggressive range (of 15-20 mg/L) and have found that not only 
it is harder to obtain in critically unwell patients and those with CrCL > 60 mL/min (32), but that it does 
not appear to convey any additional clinical benefits (32-34), except potentially a shorter treatment duration 
(Cmin ≥20 mg/L: 12.5 days, 15-20 mg/L: 13.1 days and <15 mg/L: 15.5 days; p=0.008) (32).  
Risk of vancomycin induced AKI appears to be related to Cmin concentrations attained (23, 25, 34), 
regardless of the definition for AKI used (23). A 2013 systematic review and meta-analysis by van Hal et 
al (35) found that the incidence of nephrotoxicity varied from 5-43% and occurred between 4.3 and 17 days 
after initiation. Higher Cmin values (≥15 mg/L) were associated with a higher odds ratio (OR) of 
nephrotoxicity compared to lower Cmin values (<15 mg/L) (OR: 2.67, 95% CI 1.95-3.65; p<0.01). This OR 
was even greater when the studies used were restricted to those only examined Cmin values immediately at 
steady state achievement (OR: 3.12, 95% CI 1.81-5.37; p<0.01). When looking at rates of AKI as a function 
of Cmin values, rates of nephrotoxicity increased as the concentration increased. This result is similar to 
another more recent meta-analysis which showed a curve-linear relationship (23); with a reference value of 
10 mg/L, the risk of AKI was significantly higher in patients achieving levels of 15 mg/L (OR: 1.51, 95% 
CI 1.37-1.70), 20 mg/L (OR: 1.97, 95% CI 1.59-2.45) and 25 mg/L (OR: 2.40, 95% CI 1.88-3.07). Duration 
of therapy also appears to affect risk of nephrotoxicity; courses of 7-14 days appeared to be more likely to 
result in AKI than shorter courses (35). 
 Pharmacokinetic/Pharmacodynamic target for safety and efficacy  
 AUC24/MIC 
The most recent guidelines from the IDSA (1) advocate for clinicians to use a 
pharmacokinetic/pharmacodynamic metric to monitor vancomycin rather than Cmin values; the ratio of area 
under the curve over 24 hours to the minimum inhibitory concentration (obtained from broth microdilution) 
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of the target bacteria, AUC24/MICBMD. The AUC is the measure of total exposure to a drug over a given 
period (5, 15, 36) while the MIC describes the susceptibility of a pathogen to a specific antibiotic. Clinically, 
the MIC is used to aid decision making about antibiotic choice (15). 
There are several methods of estimating MIC which are not interchangeable (15). While the 
determination by broth microdilution (BMD) is used often in clinical trials, the Etest (bioMériuex USA, 
Hazelwood, MO) is commonly used by commercial laboratories as it is less labour intensive (15), including 
CDHB. While MICEtest values tend to be 1.5 to 2 times higher than the corresponding MICBMD value (1, 26, 
37), it is the recommended method of testing bloodstream infection isolates (37). Therefore, it is important 
to state which method is used to determine the MIC when reporting values of AUC24/MIC. It has been 
recommended that it may be best to assume a MICBMD of 1mg/L; MRSA strain isolates are predominately 
1mg/L, and a global surveillance program has reported that the have been no signs of MIC creep over the 
past 20 years (1). Another key piece of information is that margin of error for MICBMD is ±1 log2 dilution 
(30); current testing methods are not able to distinguish 0.5 mg/L from 1 mg/L from 2 mg/L (1). Due to the 
margin of error, it is not recommended that clinicians make dosage adjustments solely on the MIC result 
(1, 30), and should assume a MICBMD of 1 mg/L. Alternatively, the local minimum inhibitory concentration 
to inhibit growth of 90% of organisms of S. aureus strains has been suggested as a replacement (15). 
Evidence for the metric of AUC24/MIC and minimum target is derived from mainly retrospective 
observational studies, of invasive infections (mostly bloodstream infections) in patients due to MRSA (see 
Table 1.1). The landmark study by Moise-Broder et.al (4) found that achieving a AUC24/MICBMD of ≥ 400 
significantly reduced the time to bacterial eradication (18 days if target achieved vs not ≥ 30 days) for those 
with S. aureus lower respiratory tract infections. Since this study, several groups have investigated this 
metric for the point where the clinical outcomes significantly change either using AUC24 at steady state 
(AUCss0-24h) or after 24 (AUC0-24h) or 48 (AUC24-48h) hours of therapy. AUC24/MICBMD values were found 
to be similar in those reported in the original Moise-Broder et.al study (range 373-421) and those using 
Etest for MIC determination resulted in similar results when adjusting for the different MIC test (1). A few 
studies have looked at values of AUC early in the treatment course (before steady state is achieved) and 
found that higher thresholds may need to be met earlier on in the course (AUC0-24h/MICBMD 521-600, 
AUC24-48h/MICBMD 320-650), though the recent prospective study by Lodise et al. (38) could not determine 
a significant AUC24-48h/MICBMD threshold that reduced treatment failure. Very few patients in this study 
had an AUC24-48h < 400, so the authors were unable to comment on whether this lower range was suitable 
early in the course. Based on information from these studies, the most recent IDSA guidelines recommend 
a minimum target for AUC24/MICBMD of 400 to achieve clinical outcomes without creation of resistant 
strains of S. aureus (1). 
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While a lower target of AUC for efficacy has been suggested, upper limits of exposure for safety 
have not been well quantified (39). This may be attributed to the idea that toxicity occurs on a continuum 
(5, 24) and certain populations may be at increased risk for a given AUC value (5). Several studies have 
investigated a potential upper safety threshold for AUCss0-24h (24-26). Significant increases in 
nephrotoxicity rates have been shown between AUCss0-24h of 500 and 1300 mg.h/L (5, 24, 26). A recent 
meta-analysis found that in patients with an AUC0-24h and AUC24-48h less than 650 mg.h/L, the odds of 
developing AKI was lower than those who had results greater than 650 mg.h/L (OR0-24h: 0.36, 95% CI: 
0.23-0.56; p < 0.00001, OR24-48h: 0.45, 95% CI: 0.27-0.75; p=0.002) (24). The recent 2020 Lodise et al. 
(38) prospective study found that while higher exposure to vancomycin didn’t affect rates of treatment 
failure, it increased the risk of nephrotoxicity (AUC24-48h ≥793 versus ≤343 provided statistically differing 
rates of nephrotoxicity). As the upper limit of AUC0-24h for safety is not well defined, and risk of developing 
nephrotoxicity depends on individual characteristics and risk factors, the recommended maximum value of 
AUC0-24h for vancomycin is 600 mg.h/L (1). 
Overall, the most recent IDSA guidelines recommend a target range for AUC24/MICBMD of 400-
600 for infections due to MRSA with further doses guided by the resulting AUC24/ MICBMD (1), assuming 
a MICBMD of ≤1 mg/L. This dose range is specifically recommended for infections due to MRSA, though 
is applied in practice to infections from other organisms due to a paucity of data in these infections and that 
reducing inappropriate exposure is important regardless of the infectious organism. Initial doses of 15-
20 mg/kg (based on actual weight) are recommended every 8-12 hours in patients with normal renal 
function.  
 Other Targets 
Another metric that has been investigated is the percentage of time the concentration is above the 
MIC (%T > MIC). This metric has been shown to be ineffective for monitoring vancomycin. Moise-Broder 
et al (4) compared %T > MIC to AUC24/MICBMD and found that it has limited clinical utility as a monitoring 
parameter for vancomycin dosing. The doses commonly administered for invasive infections resulted in 
concentrations above the MIC 100% of the time, even when AUC24/MICBMD was subtherapeutic. Therefore, 
%T > MIC is not recommended for monitoring vancomycin. 
The presence of a post antibiotic effect with vancomycin means that time of exposure is less 
important, rather the goal is to provide an adequate amount of vancomycin, which the AUC24/MICBMD 
measures (22). Additionally, the prolonged post antibiotic effect when compared to other antibiotics such 
as β-lactams may explain why AUC24/MICBMD has been the major pharmacokinetic/pharmacodynamic 
parameter that correlates to efficacy rather than %T > MIC (40). 
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Dialysis BMD and 
Etest 
Day 1 and 2 thresholds 
associated with 
reduced risk of 
treatment failure4 
AUC0-24h/MICBMD ≥521 
(RR: 0.6, 95%CI 0.3-0.9; p=0.03) 
AUC0-24h /MICEtest ≥303 
(RR: 0.5, 95%CI 0.3-0.9; p=0.01) 
AUC24-48h/MICBMD ≥650 
(RR: 0.5, 95%CI 0.3-0.9; p=0.02) 
 
1 Culture-proven eradication from sputum or absence of culture material due to clinical improvement 
2 Defined as 30-day mortality, persistent signs and symptoms at end of therapy, bacteraemia ≥7 days 
3 Microbiological clearance defined as ≥2 consecutive negative blood culture results 



















Treatment failure5 AUCss 0-24/MICBMD <398.5 
(associated with treatment failure; 
p=0.065) 
AUCss 0-24/MICEtest <430 
















Day 1 vancomycin 
exposure and treatment 
failure6 
AUC0-24h/MICBMD > 600 
(54.7% versus 69.8% failure; p=0.073) 
AUC0-24h/MICEtest > 290 














Day 2 AUC/MIC 
target to treatment 
failure 
No significant thresholds identified. 
AUC24-48h/MICBMD ≥650 
(22% failure vs 15%, p=0.15) 
AUC24-48h/MICEtest ≥320 
(21% failure vs 11%, p=0.07) 
 
 
5 Composite of persistent bacteraemia (infection present despite 7 day’s vancomycin therapy), 30-day all-cause mortality, recurrence of bacteraemia within 60 days after 
completion of therapy 
6 Defined as persistent bacteraemia for ≥7 days and/or death within 30 days of initial positive culture 
Table 1.1: Descriptive details of available clinical trials investigating optimal AUC24/MIC for various indications and treatment outcomes. AUCss0-24h represents the AUC24 
for doses at steady state, AUC0-24h represents the AUC for the first 24 hours of therapy and AUC24-48h represents the AUC for the second 24 hours of therapy. 
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 Pharmacokinetic versus Pharmacokinetic-Pharmacodynamic targets 
There has been a shift in the recommended method used to monitor vancomycin in the IDSA 
guidelines released in 2009 (28) to 2020 (1), from the use of Cmin, to using the 
pharmacokinetic/pharmacodynamic metric AUC24/MICBMD. The guidelines released in 2009 recommended 
monitoring Cmin concentrations as a surrogate marker for what was considered the more robust metric of 
AUC24/MICBMD, assuming the MIC of the target organism was ≤1mg/L (1, 28). The rationale for monitoring 
Cmin was that AUCss0-24 is not readily calculated in practice due to the perceived difficulty of the calculation 
(5, 28) and that a Cmin concentration between 15-20 mg/L would generally correlate to an AUCss0-24h of at 
least 400 mg.h/L (5). Historically, the calculation of AUCss0-24h required the use of the trapezoidal method 
(see Section 1.2.2.5.2 below); this is not practical for clinicians, nor patients, as it requires several samples 
from the individual over a dosing interval. (46). Since the 2009 IDSA guidelines, there has been a 
proliferation in software options available which aid in the conversion of plasma drug concentrations values 
to AUCss0-24h (47). 
While Cmin monitoring has been well ingrained in clinical practice, due to its simplicity, there is a 
discrepancy between Cmin and the AUCss0-24h (5); this relationship is affected by inter- and intra-individual 
variability. Firstly, it is not possible to accurately and reliably predict the overall exposure to a dose in an 
individual (i.e., the AUC) from a single point concentration without accounting for individual covariates 
(5, 48). Pai et al. (5) demonstrated how poorly Cmin plasma concentrations were at being a surrogate marker 
for AUCss0-24h using a 5000-patient Monte Carlo simulation (with a fixed dosing schedule). The Cmin plasma 
concentration was unable to explain more than half of the observed interpatient variability in the 
relationship between Cmin plasma concentration and AUC24 (R2=0.409). Additionally, many patients will be 
able to meet the AUCss0-24h target with a Cmin plasma concentration of <15 mg/L (15, 26, 31, 48, 49). One 
study found that 55% of their sample population were able to achieve an AUCss0-24h of > 400 mg.h/L while 
recording a Cmin < 15 mg/L (50). Secondly, Cmin concentrations are impacted by the dosing frequency (e.g., 
for the same total daily dose in the same patient, Cmin will be different in 12-hourly dosing versus 8-hourly 
dosing). Drennan et al. (15) demonstrated when targeting a Cmin of 15 mg/L for a 70 kg individual with a 
glomerular filtration rate of 120 mL/min when administering vancomycin 12-hourly, 6-hourly and by a 
continuous infusion, the resulting AUCss0-24h varied considerably: 370 mg.h/L, 500 mg.h/L and 630 mg.h/L 
respectively. While the value of Cmin was consistent, the corresponding AUCss0-24h varied by almost 
300mg.h/L due to the dosing schedule used. The variability in the relationship between Cmin and AUCss0-
24h significantly affects the use of Cmin as a surrogate marker; without accounting for the individual dosing 
regimen and pharmacokinetic variations between patients, it is possible that while an individual seems to 
be in the target Cmin range, the AUCss0-24h could be erroneously low or high. 
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An additional concern is that dosing vancomycin using Cmin concentrations appears to result in 
higher rates of nephrotoxicity. The prospective study by Neely et al. (51) found patients dosed by Cmin (to 
10-20 mg/L) in the first year of the study had higher rates of nephrotoxicity compared to those dosed by 
AUCss0-24h in the subsequent two years (8%, 0%, 2% respectively; p=0.02). Finch et al. (52) similarly 
reported that monitoring and dosing vancomycin by AUCss0-24 (accounting for severity, comorbidity and 
concomitant nephrotoxic use), resulted in lower odds of developing nephrotoxicity than by Cmin 
concentrations (OR: 0.51, 95% CI 0.33-0.79, p=0.003). Other groups who have converted from Cmin 
monitoring to AUC-based monitoring have found a non-significant reduction in nephrotoxicity rates (50). 
This reduction in nephrotoxicity appears to be related to a reduction in vancomycin exposure (52); 
individuals who were dosed by Cmin concentrations were seen to have higher Cmin concentrations as well as 
AUCss0-24 values (51-53). This may be impacted by how a clinician interprets a reported Cmin result. Dosing 
regimens may be incorrectly adjusted based on a low Cmin result when the corresponding AUCss0-24h is 
within the correct range, resulting in an excessively high AUCss0-24 (15, 26). This is especially an issue as 
Cmin results of 15-20 mg/L are associated with higher rates of nephrotoxicity than <15 mg/L (23, 30). 
 Estimation of AUCss0-24h 
The AUCss0-24h for an individual can be estimated by one of several methods as outlined below.  
 Trapezoidal method 
The trapezoidal method determines AUC0-tau (where tau represents the end of a dosing period) by 
taking a plasma concentration-time plot, breaking it up into trapezoids and then summing the area of each 
(46). This can then be extrapolated to AUC0-24h by multiplying the AUC0-tau by the number of dose periods 
in 24 hours. This method tends to have error: overestimating the descending phase and underestimating the 
ascending phase (46). The main limitation of this method is that at least three to four samples are required, 
and more are needed to improve the estimate (46). 
 Limited sampling strategies 
1.2.2.5.2.1 Empirical estimates 
AUCss0-24h can be determined using empirical estimates. Several equations, often based on dosing 
and renal function data, exist (17, 54, 55). The equation derived by Rodvold et al (17) is commonly referred 
to in the literature and is presented in Equation 1.1: 
𝐴𝑈𝐶𝑠𝑠0−24ℎ =
𝑇𝑜𝑡𝑎𝑙 𝐷𝑎𝑖𝑙𝑦 𝐷𝑜𝑠𝑒
([𝐶𝐿𝐶𝑅 × 0.79] + 15.4) × 0.06
 
Equation 1.1: Method of calculating AUC0-24h Rodvold et al (17) utilising total daily dose and creatinine clearance (CLcr). 
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AUCss0-24h determined using empirical equations have been shown to overestimate the vancomycin 
clearance by up to 50% and when utilizing a similar formula to Equation 1.1, Lodise et al. (43) found poor 
correlation between the predicted concentration and the observed concentration. While this calculation is 
easy and simple to use, it potentially oversimplifies the issue. These empirical estimates also require the 
individual to be at steady state and do not account for the resulting vancomycin concentrations (and so these 
cannot be incorporated into the estimate) which limits their use. Current guidelines recommend that these 
creatinine clearance (CLcr) based formulae are not used due to their inaccurate nature (1). 
1.2.2.5.2.2 Model based estimates 
AUCss0-24h can be estimated using pharmacokinetic principles and what has been called the 
Sawchuk-Zaske method (5). Essentially, this method assumes a one-compartmental pharmacokinetic model 
and uses at least two plasma samples within the same dosing interval (5, 37). The calculated AUC can then 








Equation 1.2: Equation to obtain elimination rate constant.C1 and C2 are the two measured concentrations and ∆𝑇 represents the 
difference in time. 
𝐶𝑚𝑎𝑥 = 𝐶1 × 𝑒
𝑘×∆𝑇 
Equation 1.3 Equation to obtain Cmax, C1 is the concentration, k is the elimination rate constant and ∆𝑇 is the difference in time 
between the concentration sample and Cmax. 
𝐶𝑚𝑖𝑛 = 𝐶2 × 𝑒
−𝑘×∆𝑇 
Equation 1.4 Equation to obtain Cmin, C2 is the concentration, k is the elimination rate constant and ∆𝑇 is the difference in time 





Equation 1.5 Equation to obtain AUC for a dose using the estimated Cmax (Equation 1.3), Cmin (Equation 1.4) and k (Equation 1.2) 
𝐴𝑈𝐶𝑠𝑠0−24ℎ =
𝐴𝑈𝐶𝑑𝑜𝑠𝑒
𝜏⁄ × 24 
Equation 1.6: Extrapolation of AUCdose to AUCss0-24h using the maintenance frequency (τ) 
The Sawchuk-Zaske method has specific limitations. Firstly, Equation 1.6 requires two samples 
from the patient. While this is less than for the trapezoidal method, it is more than for Cmin monitoring. 
Secondly, this method is impacted by the timing of drug concentration measurements. If samples are 
measured early in the dosing interval (in the alpha distribution phase), then the value of Cmax and AUCdose 
will be overestimated, and later samples (in the beta distribution phase) will underestimate Cmax and 
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AUCdose. This is because this method assumes that vancomycin is explained by a one-compartmental model 
and that the elimination rate constant does not change between the two samples (5). It is generally accepted 
that vancomycin is best explained by a two-compartmental model (6). Thirdly, this method requires 
accurate recording of dose and sample times (15). Finally, this method ignores all exposure to vancomycin 
during the infusion itself (as it only goes from Cmax to Cmin), which could be a problem for vancomycin due 
to its requirement of a long infusion time. 
From the first-order equations it is possible to estimate the AUCss0-24h from the daily dose and the 
observed plasma concentrations. As Cmax can be substituted by 𝐶𝑚𝑖𝑛 + 𝑑𝑜𝑠𝑒 𝑉𝑑⁄ , and the 𝐴𝑈𝐶0−24ℎ =
 𝑇𝑜𝑡𝑎𝑙 𝑑𝑎𝑖𝑙𝑦 𝑑𝑜𝑠𝑒 𝑑𝑟𝑢𝑔 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒⁄ , the following formulae can be derived (36): 









Equation 1.7 Equation to estimate AUC24 using the daily dose, volume of distribution (which can be estimated at 0.7 L/kg) and one 
plasma sample. 
This method does not require knowledge of the individual’s Vd; It is possible to use a population 
estimate of Vd (e.g. 0.7 L/kg (36)), though this may introduce significant prediction error. Therefore 
Equation 1.7 can be used to estimate AUCss0-24h from one plasma concentration and the total daily dose or 
a mg/kg dose. 
 Bayesian dose forecasting 
Bayesian dose forecasting can be used to estimate an individual’s AUCss0-24h. While Bayesian dose 
forecasting is more mathematically demanding than other methods, the existence of user-friendly software 
makes it easier for the end user (30). Bayesian dose forecasting has several advantages over other methods 
(5): concentrations can be obtained at any time (they are not limited to Cmax or Cmin), algorithms can account 
for an individual dosing regimen – even if it changes and they can estimate AUCss0-24h from plasma samples 
taken prior to achieving steady state. These methods have been shown to improve the percent of patients 
achieving AUC24/MICBMD targets compared to empirical dose adjustments (56). 
1.2.2.5.3.1 Overview of Bayesian forecasting  
Bayesian dose forecasting uses an existing model for population pharmacokinetics, individual 
characteristics (including dose regimen), and measured plasma concentrations to predict drug exposure (15, 
57). The population pharmacokinetic model (prior model), along with any patient factors (e.g., body weight) 
that might predict individual pharmacokinetic parameters such as CL and V, can be used to provide a 
‘population’ prediction of drug response (adjusted for individual patient factors). These predictions can be 
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further individualised by incorporating individual drug response measures, e.g., plasma drug 
concentrations. The forecasting software uses a search algorithm to find the maximum value of an objective 
function value (equation 1.8) given the data to determine the best fit individual pharmacokinetic parameters. 
The tool then estimates the individual response for each subject. CDHB has access to the dose 
individualisation software TCIWorks (57), the output from which is not a full posterior distribution for each 
pharmacokinetic parameter, but a point estimate. TCIWorks therefore uses a Maximum a posteriori (MAP) 
objective function (57). Once an individualised pharmacokinetic profile has been generated by TCIWorks, 
metrics such as AUCss0-24h can then be estimated. TCIWorks estimates AUCss0-24h using the linear 
trapezoidal method. 
𝑀𝐴𝑃𝑜𝑏𝑗 = ∑














Equation 1.8: Maximum a posteriori function. MAPOBJ is the MAP objective function, yj is the jth observation, g(θ, xj) is the model-
predicted jth observation, θ is a vector of individual parameter estimates, 𝜎𝑦𝑗
2  is the residual variance associated with the jth 
observation (which is equal to 𝜎𝑝𝑟𝑜𝑝
2 ∙ 𝑔(𝜃, 𝑥𝑗)
2 where 𝜎𝑝𝑟𝑜𝑝
2  is the proportional variance, ln θp is the natural log of the pth 
parameter, ln µp is the natural log of the prior population value of the pth parameter and 𝜔𝜃𝑝
2  is the log-normal inter-individual 
variance associated with the pth parameter (57) 
1.2.2.5.3.2 Use of MAP estimators for vancomycin dosing 
Estimation of AUCss0-24h needs to fit within clinical workflows and produce an accurate estimate. 
Methods such as the trapezoidal method do not fit well due to the number of samples required and the 
empirical or model-based estimates have limitations which impact accuracy and utility. Obtainment of Cmin 
concentrations has been well ingrained into clinical practice; using this strategy combined with software 
that implements a MAP estimator and prior model could bridge the gap between observed Cmin results and 
AUCss0-24h early in the treatment course without increasing demand on ward staff or patients. 
To date, only a handful of studies have investigated the accuracy of AUCss0-24 estimated from 
limited sampling strategies (5, 48, 51, 58-60). Accuracy of the estimate appears to be affected by several 
factors; 1) the prior model used (and how it relates to the test cohort), 2) the search algorithm incorporated 
into the software used, 3) the plasma concentration sampling strategy used and 4) obesity status of the 
individual (see Section 1.2.2.5). Overall, the published literature suggests that it is possible to estimate 
AUCss0-24h with a limited sampling strategy with minimal bias from software that implements a MAP 
estimator, provided the prior model is derived from a richly sampled, diverse cohort. The 2020 IDSA 
vancomycin guidelines recommend using Bayesian software solutions which use a prior model based on 
richly sampled data as the preferred method of AUC24/MICBMD monitoring (1). 
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 Vancomycin dosing in obese patients 
Obese patients present a unique challenge; there is a paucity of data on accuracy of limited sampling 
strategies in obese individuals. Increases in body weight impact on pharmacokinetic properties of 
medications. As previously described, the Vd for vancomycin do not appear to scale proportionally to 
weight and so loading doses based on total body weight may overdose obese individuals. Maintenance 
doses of medications are based around the estimated clearance, for vancomycin this is predicted from 
kidney function which is calculated by methods which have limitations in those who are obese (61). 
Data on the estimation of AUCss0-24h from a limited sampling strategy in obese individuals is scant. 
Overall, the literature suggests that the estimation of vancomycin AUCss0-24 in obese individuals may not 
be well estimated from a single concentration. A pilot study of 12 obese patients (62) was undertaken to 
estimate a population model in obese patients as well as ascertaining the best method of estimating the 
AUCss0-24h. Comparing the model derived from the study’s 12 patients to other models derived from non-
obese subjects, the authors found that when using Cmin-only data, using a prior model from non-obese 
subjects as the Bayesian prior produced biased results. When the obese cohort’s data was used, the relative 
bias did include the null value of 1 but, the results were more imprecise. The addition of a second level 
(taken one hour after the infusion) significantly improved the bias and imprecision; one of the models taken 
from a non-obese cohort performed better than the study-derived one in this instance. Pai et al. (63) found 
that Cmax and Cmin samples (with a one-compartmental model derived from obese subjects) was able to 
explain the vancomycin concentration-time data significantly better than with Cmin only data (using the 
traditional two-compartmental covariate-dependent model).  
Since the limited data available shows improvement in bias and imprecision with the addition of 
Cmax concentrations in obese individuals, the 2020 IDSA guidelines recommend using a Cmax and Cmin 
sample for the initial measurement, with subsequent measurements being Cmin only (1). They also 
recommend the same proportional dose of 15-20 mg/kg for obese individuals with a cap of 3000 mg to 




 Simulation study design 
A simulation study was conducted using vancomycin plasma concentrations predicted from a 
published population pharmacokinetic model (2) implemented in NONMEM (v7.3) and TCIWorks (v1.0-
RC1). A brief overview of the study design is provided here and followed by specific details about the 
model and data analysis. 
The overall study design was as follows: 
1. Vancomycin plasma concentrations at each hour were simulated from therapy initiation to day 
11 (assumed steady-state) using a published population pharmacokinetic model from Thomson 
et al. (2) implemented in NONMEM. Dosing and baseline patient characteristics (weight, 
height, age, serum creatinine and sex) were extracted for each simulate from an existing dataset 
of patients who had undergone vancomycin therapeutic drug monitoring, held by the 
Department of Clinical Pharmacology at Christchurch Hospital (referred to here as the ChCh 
TDM dataset). The data available is described in detail below, including the derivation of 
variables such as CLcr. In brief, vancomycin dosing histories and patient characteristics were 
available for 178 patients. Note that observed plasma concentrations were available in this 
dataset but were not used as part of the present study. Instead, the plasma concentration at each 
hour across 11 days of vancomycin therapy was predicted from the pharmacokinetic model for 
simulated individual using the post-hoc MAP functionality in NONMEM. 
2. A reference steady state area-under-the-plasma-concentration-time curve across 24 hours on 
Day 10 (AUCssRef: 0-24h) was determined using predicted plasma concentrations (see Appendix 
5.1). 
3. The same baseline patient characteristics and dosing history were entered into TCIWorks; 
a. Vancomycin dosing history for 11 days of therapy. If therapy ceased prior to the 11th 
day, the last dose and frequency was carried forward to day 11. 
b. Baseline patient characteristics and derived variables including the patient’s weight 
and CLcr.  
4. A test area-under-the-plasma-concentration-time curve across 24 hours on Day 10 
(AUCssTest: 0-24h) was determined using the following limited sampling strategies (see Appendix 
5.2 for the code used). The strategies were chosen for several reasons: to align with existing 
clinical workflows, to see whether the estimated AUCssTest: 0-24h could be used clinically and 
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were early enough in the treatment course that the rapid attainment of the therapeutic range 
could be achieved: 
a. No vancomycin plasma concentrations entered into TCIWorks (“prior model only”) 
b. Cmin (minimum concentration and time for a dose) plasma concentrations for the: 
i. 1st dose 
ii. 2nd dose 
iii. 3rd dose 
iv. 4th dose 
v. 5th dose 
vi. 2nd dose and the 3rd dose 
c. Cmin and Cmax samples (maximum concentration and respective time after dose 
initiation) for the: 
i. 1st dose 
ii. 2nd dose 
Plasma concentrations for each test were taken from those predicted by the MAP function in 
NONMEM (described above) for each individual. 
5. The AUCssRef: 0-24h was compared to the AUCssTest: 0-24h (see Section 2.2.1 below) to assess bias 
and imprecision. 
 Data Analysis 
 Comparison of AUCssTest: 0-24h and AUCssRef: 0-24h 
The AUCssTest: 0-24h was compared to the AUCssRef: 0-24h using measures of bias and imprecision. The 
following metrics were calculated for each of the limited sampling strategies described above (57): 
1. The mean prediction error (MPE) and 95% confidence interval (CI) (Equation 2.1). If the 
95% CI of MPE included zero, then no bias between the limited sampling strategy and the 
reference was concluded. 







Equation 2.1: Equation for calculating the mean prediction error (mg.h/L) for a limited sampling strategy limited sampling strategy 
on an individual. N represents the number of individuals and PEi is the prediction error (the estimated AUCTest minus the AUCRef) 




2. The mean square prediction error (MSE, Equation 2.2) and root mean square error 
(RMSE, Equation 2.3) was calculated as a measure of imprecision: 








Equation 2.2: Determination of the mean square prediction error. N represents the number of individuals and PEi is the prediction 
error (the estimated AUCTest minus the AUCRef) for the ith individual and test scenario. 
𝑅𝑀𝑆𝐸 =  √𝑀𝑆𝐸 
Equation 2.3: Conversion of mean square prediction error to root mean square error. 
𝑅𝑃𝐸 = 100 × (𝑃𝐸 𝐴𝑈𝐶𝑠𝑠𝑅𝑒𝑓: 0−24ℎ⁄ ) 
Equation 2.4: Equation for calculating the relative prediction error (%) per individual and sampling strategy combination. PE 
represents the absolute difference between AUCssTest: 0-24h and AUCssRef: 0-24h. 
3. The geometric mean for the ratio of AUCssTest: 0-24h to AUCssRef: 0-24h (AUCssTest: 0-
24h/AUCssRef: 0-24h) and the 90% CI of this value. In this case, no significant bias was 
concluded if the 90% CI of the ratio was within 0.90-1.11 without rounding (e.g., 0.899-
1.050 or 0.950-1.112 would not be considered bioequivalent). Note that this is narrower 
than the standard 0.80-1.25, as suggested in bioequivalence studies for narrow therapeutic 
range drugs (64).  
4. The proportion of values where the value of AUCssTest: 0-24h was within 20% of AUCssRef: 0-
24h (P20) and a 95% CI of this estimate. This metric was determined for each limited 
sampling strategy that met bioequivalence according to (3) above. Statistical significance 
between P20 values was identified by the Cochran’s-Q test with post hoc analysis 
undertaken by pairwise McNemar tests; p-values were adjusted for multiple comparisons 
using the Bonferroni correction. 
5. Confidence intervals for the above measures were calculated using the R function, confint. 
on a t.test and binomial test using the Clopper-Pearson procedure (for the MPE and P20 
respectively) and from the R function, Gmean (for the AUCssTest: 0-24h/AUCssRef: 0-24h) from 
the DescTools package which calculates confidence intervals by a t.test. 
 Effect of obesity on AUC prediction  
To assess the impact of obesity on AUCssTest: 0-24h prediction, the results were stratified into obese 
and non-obese individuals (obesity was defined as a body mass index (BMI) greater than or equal to 




 Factors that contribute to bias in in the AUCssTest: 0-24h estimate 
A multi linear regression model was created for each sampling strategy that met the bioequivalence 
criterion in Section 2.2.1 to identify significant factors that contributed to the prediction error in the 
AUCssTest: 0-24h estimate. The prediction error for each individual was used as the outcome variable and 
demographic factors were used as explanatory variables: sex, age, ethnicity, BMI, baseline serum 
creatinine, limited sampling strategy and maintenance frequency. The model was simplified using the 
Akaike Information Criteria (AIC) to obtain significant covariates. All explanatory variables were included 
initially and removed sequentially if the value of the AIC improved significantly with its removal. A 
significance level of 0.05 was used. The reference value was set as: NZ European/Pākehā male, and 
maintenance 𝜏 of 12 hours as it represented the most subjects. 
 ChCh TDM data used for sampling patient factors and doses 
Dosing and patient characteristics (weight, height, age, ethnicity, serum creatinine and sex) were 
sampled for each simulated individual from an existing dataset of vancomycin patients held by the 
Department of Clinical Pharmacology at Christchurch Hospital as part of the Therapeutic Drug Monitoring 
service. This dataset consisted of all adult inpatients at the CDHB who were prescribed and given 
vancomycin between 2016 and 2019. Ethics approval was provided for this use of data (Human Ethics 
Application HD20/069). 
 Exclusion criteria 
Data in the ChCh TDM data file that was not suitable for sampling and therefore could not be used 
for the simulation study was excluded. The following exclusions were applied:  
• Patients on dialysis 
• Patients missing data: dosing, age, weight, height, sex or baseline serum creatinine.  
• Patients who were administered only a single dose of vancomycin 
• Patients with a calculated CLcr < 30mL/min 
Subjects with a calculated CLcr of <30mL/min or on dialysis were not included in the simulations 
due to uncertainty about the predictive performance of the Thomson model in this patient group. Since the 
ChCh TDM dataset was collated from the CDHB’s electronic prescribing and administration system, 
individuals in the intensive care unit and emergency departments were also excluded from the present study. 
 Data derived variables 
BMI was calculated via Equation 2.5, CLcr was calculated from the Cockcroft-Gault formula 
(Equation 2.6) using the total body weight (to align with the calculation used in the pharmacokinetic model 
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– see Section 2.4), the maintenance frequency was obtained from Equation 2.7 and the duration of each 
dose from Equation 2.8. Age was also rounded to the nearest year to allow consistent input into the two 
systems. 
𝐵𝑜𝑑𝑦 𝑀𝑎𝑠𝑠 𝐼𝑛𝑑𝑒𝑥 (𝑘𝑔 𝑚2⁄ ) =  
𝑇𝑜𝑡𝑎𝑙 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
𝐻𝑒𝑖𝑔ℎ𝑡 (𝑚)2⁄
  
Equation 2.5: BMI calculation using total body weight and height. 
𝐶𝐿𝑐𝑟 (𝑚𝐿 𝑚𝑖𝑛⁄ ) =  
(140 − 𝑎𝑔𝑒 ) × 𝑡𝑜𝑡𝑎𝑙 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
𝑝𝑙𝑎𝑠𝑚𝑎 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 (µ𝑚𝑜𝑙/𝐿)   × 0.8
  (× 0.85 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒) 
Equation 2.6: Cockcroft-Gault formula for CLcr. 
𝑀𝑎𝑖𝑛𝑡𝑒𝑛𝑎𝑛𝑐𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 (ℎ𝑜𝑢𝑟𝑠) = 24 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑜𝑠𝑒𝑠 𝑝𝑒𝑟 24 ℎ𝑜𝑢𝑟𝑠⁄  
Equation 2.7: Maintenance frequency (τ) calculation, where number of doses per 24 hours was an integer in the original dataset. 
𝐼𝑛𝑓𝑢𝑠𝑖𝑜𝑛 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑚𝑖𝑛𝑠) = (
𝐴𝑑𝑚𝑖𝑛𝑠𝑡𝑒𝑟𝑒𝑑 𝑑𝑜𝑠𝑒 (𝑚𝑔)
500
⁄ ) × 30 
Equation 2.8: Maintenance frequency calculation, where number of doses per 24 hours was an integer in the original dataset. 
Doses were assumed to take 30 minutes per 500 mg administered as this is the standard of care at CDHB at the time of the study. 
Data was handled using R (version 4.0.5) in RStudio (desktop version 1.4.1717) to extract relevant 
information from the original dataset. The R code is available in Appendix 5.1. 





 The vancomycin pharmacokinetic model 




CL (L/hr) 2.99 2.85-3.13 27 24-31 
θCLCR 0.0154 0.0144-0.0165   
V1 (L/kg) 0.675 0.637-0.713 15 8-21 
V2 (L/kg) 0.732 0.543-1.090 130 88-150 
Q (h-1) 2.28 1.68-2.90 49 34-81 
Table 2.1: Covariates from Thomson model (2). CL, estimate of clearance for CrCL of 66mL/min. θCLCR, proportional change in 
CL with CrCL (calculated using Cockcroft-Gault method with TBW), V1 & V2, volume of distribution for the central and peripheral 
compartments respectively. Q, intercompartmental clearance. 
The parameters reported by Thomson et al (2) 
for the vancomycin pharmacokinetic model 
implemented in NONMEM and TCIWorks are detailed 
in Table 2.1. This model is derived from 398 patients 
from the United Kingdom, details for which is available 
in Table 2.2. The Thomson model is a two-compartment 
pharmacokinetic model with first order elimination. 
CLcr (calculated using Equation 2.6 using total body 
weight) is the only covariate on CL and total body 
weight is the only covariate on the central and peripheral 
compartment volume. Equation 2.9 depicts the model 
used to calculate CL. 
𝐶𝐿 (𝐿 ℎ⁄ ) = 2.99 × (1 + θCLCR × (𝐶𝐿𝑐𝑟 − 64)) 
Equation 2.9: CL model used in the Thomson (2) publication using 
CLcr and 𝜃𝐶𝐿𝐶𝑅 . 
Demographic data  
Males (%) 63 
Age (years) 66 [16-97] 
Weight (kg) 72 [40-159] 
Obese (%) 19 
Initial SCr (µmol/L) 98 [30-573] 
Initial CLcr (mL/min) 64 [12-216] 
Pharmacokinetic data  
Number of samples 1557 
Initial dose (mg) 1000 [500-1750] 
Concentration (mg/L) 12.1 [2.0-49.2] 
Samples per patient 3 [1-19] 
Time after start of infusion 
(h) 
11.9 [1.1-92.3] 
Follow-up period (days) 4.9 [0.5-44.4] 
Table 2.2: Demographic and pharmacokinetic data for 
subjects used in the Thomson model. Results are represented 




 The ChCh TDM dataset used for sampling 
The ChCh TDM dataset contained information on 178 patients. Patient demographics and 
vancomycin dosing information is presented in Table 3.1. Of the 178 patients in the ChCh TDM dataset, 
138 contained suitable data that could be sampled for the simulation study. Forty individuals who were 
missing demographic details needed for the simulations (i.e., weight, height, serum creatinine, age) and 
vancomycin dosing histories were excluded (see Table 3.2). Demographic details for the individuals 
included in the simulation study after excluding these patients are presented in Table 3.3, stratified by 





 N Statistic 
Age (years) 163 66 [17-97] 
Sex 178  
- Male  121 (68.0%) 
- Female  57 (32.0%) 
Height (cm) 162 170.0 [140-199] 
Total body weight (kg) 155 80 [40-180] 
Body mass index (kg/m2) 148 27.6 [14.3-68.6] 
Ethnicity 177  
- NZ European/Pākehā  145 (81.9%) 
- Māori  12 (6.8%) 
- Pacific Islander  6 (3.4%) 
- Other  14 (7.9%) 
CLcr (mL/min) 155 83 [8-302] 
Dose 1 amount (mg) 163 1500 [500-2000] 
Dose 2 amount (mg) 160 1000 [200-2500] 
Dose 3 amount (mg) 148 1000 [200-2500] 
Dose 4 amount (mg) 123 1000 [200-2000] 
Dose 5 amount (mg) 78 1000 [200-2500] 
Serum creatinine at dose 1 (µmol/L) 163 87 [36-524] 
Frequency of maintenance dose (hr) 162  
- 6  1 (0.6%) 
- 8  2 (1.2%) 
- 12  157 (96.9%) 
- 24  2 (1.2%) 
Patient on dialysis 176  
- Yes  3 (1.7%) 
- No  173 (98.3%) 
Table 3.1: Patient demographics and vancomycin dosing for the complete ChCh TDM data prior to exclusions. Categorical 





Exclusion rationale N 
Missing age 15 
Missing height 16 
Missing weight 23 
CLcr < 30mL/min  10 
Missing serum creatinine 15 
Missing maintenance dose or frequency 18 
On dialysis or missing dialysis details 5 
Total excluded 40 
Table 3.2: Details of the exclusions from the ChCh TDM dataset. Note 




 Obesity status  
 Obese Non-obese Total 
 (N=56) (N=82) (N=138) 
Age (years)  65.0 [23-81] 65.0 [19-93] 65.0 [19-93] 
Sex                                   
  - Male                           40 (71.4%) 50 (61.0%) 90 (65.2%) 
  - Female                         16 (28.6%) 32 (39.0%) 48 (34.8%) 
Height (cm)                        173 [149-199] 171 [145-195] 172 [145-199] 
Total body weight (kg) 105 [74-180] 71 [42-102] 84 [42-180] 
Body mass index (kg/m2) 35.1 [30.0-68.6] 24.8 [18.1-29.7] 28.2 [18.1-68.6] 
CLcr (mL/min) 93.1 [39.6-301.8] 72.2 [30.0-161.9] 84.5 [30.0-301.8] 
Baseline serum creatinine 
(µmol/L) 
88 [57-175] 84 [36-252] 86 [36-252] 
Ethnicity                             
  - NZ European/Pākehā   43 (76.8%) 70 (85.4%) 113 (81.9%) 
  - Māori                          6 (10.7%) 2 (2.4%) 8 (5.8%) 
  - Pacific Islander  6 (10.7%) 0 (0.0%) 6 (4.3%) 
  - Other                          1 (1.8%) 10 (12.2%) 11 (8.0%) 
Table 3.3: Descriptive statistics of individuals included in the simulation study after exclusion criteria. Categorical variables are 
represented by count (and proportion) while continuous variables are represented by median and range. 
In total, 3047 doses of vancomycin were simulated (median dose 1000 mg [200 mg-2500 mg]); 
Table 3.4 depicts the descriptive statistics of the simulated doses. Obese individuals received higher doses 




 Obesity status  
 Obese Non-obese Total 
Dose 1 amount (mg) 2000 [900-2000] 1500 [1000-2000] 1500 [900-2000] 
Dose 2 amount (mg) 1000 [375-2500] 1000 [200-2000] 1000 [200-2500] 
Dose 3 amount (mg) 1000 [275-2500] 1000 [200-2000] 1000 [200-2500] 
Dose 4 amount (mg) 1000 [275-2000] 1000 [200-1750] 1000 [200-2000] 
Dose 5 amount (mg) 1000 [400-2000] 1000 [200-2500] 1000 [200-2500] 
Dose 1 mg/kg                       16.7 [7.35-23.26] 23.0 [10.31-33.33] 19.8 [7.35-33.33] 
Dose 2 mg/kg                       9.6 [4.31-21.74] 13.3 [4.44-33.33] 11.7 [4.31-33.33] 
Dose 3 mg/kg                       9.5 [3.16-21.74] 13.2 [4.44-30.30] 11.5 [3.16-30.30] 
Dose 4 mg/kg                       9.5 [3.16-21.74] 13.6 [4.44-23.08] 11.6 [3.16-23.08] 
Dose 5 mg/kg                       10.0 [4.35-18.99] 13.2 [4.44-38.46] 11.9 [4.35-38.46] 
Frequency of maintenance dose 
(hr) 
   
  - 8                              1 (1.8%) 1 (1.2%) 2 (1.4%) 
  - 12                             54 (96.4%) 81 (98.8%) 135 (97.8%) 
  - 24                             1 (1.8%) 0 (0.0%) 1 (0.7%) 
AUCssRef: 0-24h  628 [172, 1557] 610 [172, 1726] 618 [172, 1726] 
Table 3.4: Descriptive statistics for simulated doses stratified by obesity status. Values represent median [range] for continuous 




 AUCssTest: 0-24h versus AUCssRef: 0-24h 
The overall agreement between AUCssTest: 0-24h and AUCssRef: 0-24h is graphically depicted in Figure 
3.1 and Figure 3.2. These plots suggest an apparent negative bias, i.e., that AUCssTest: 0-24h is on average 
lower than the corresponding AUCssRef: 0-24h. Figure 3.2 presents a series of Bland-Altman plots where the 
line of best fit shows a negative slope, also suggesting a proportional negative bias, where this bias in 
AUCssTest: 0-24h becomes greater as the value increases. The individual prediction errors are depicted in 
Figure 3.3. 
 




Figure 3.2: Bland-Altman plot representing overall agreement between AUCssTest: 0-24h and AUCssRef: 0-24h by limited sampling 
strategy, solid blue line represents mean difference between AUCssTest: 0-24h and AUCssRef: 0-24h and dashed represent the 95% limits 




Figure 3.3: Prediction error of the AUCssTest: 0-24h estimate with each test scenario. Each box represents the median, 25th and 75th 
percentile of the prediction error and whiskers extend to the value no further than 1.5 times the interquartile range. Points indicate 
potential outliers. 
The relative difference of AUCssTest: 0-24h from AUCssRef: 0-24h for each sampling strategy can be 
seen in Figure 3.4, which depicts the mean value of AUCssTest 0-24h and AUCssRef: 0-24h by the difference of 
the values divided by the mean value of the two values. This plot depicts a moderate relative difference 
between AUCssTest 0-24h and AUCssRef: 0-24h, particularly at lower values of AUCssTest 0-24h. Figure 3.5 depicts 
the relative prediction error by limited sampling strategy; a value of 0% represents no difference between 




Figure 3.4: Relative difference plot depicting the difference of AUCssTest 0-24h and AUCssRef: 0-24h by limited sampling strategy, solid 
blue line represents mean relative difference between AUCssTest: 0-24h and AUCssRef: 0-24h and dashed represent the 95% limits of 





Figure 3.5: Relative prediction error of the AUCssTest: 0-24h estimate with each limited sampling strategy. Each box represents the 
median, 25th and 75th percentile of the prediction error and whiskers extend to the value no further than 1.5 times the interquartile 
range. Points indicate potential outliers. 
Measures of bias and precision as well as the AUCssTest: 0-24h/AUCssRef: 0-24h and P20 are summarised 
in Table 3.5. All limited sampling strategies resulted in a significant negative bias for the prediction of 
AUCssRef:0-24h. Only one sampling strategy produced a value of AUCssTest:0-24h/AUCssRef:0-24h that fell within 
the bioequivalence range, the Cmins from doses 2 and 3 (0.927, 95% CI 0.902-0.953) which resulted in a 
P20 of 72% (95% CI 64-80%). Since this was the only sampling strategy to meet the bioequivalence criteria 
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Table 3.5: Measures of bias and imprecision for all included individuals. Values are means with range defined in each column AUCssTest: 0-24hAUCssRef: 0-24h is the geometric mean.  
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 Effect of obesity on AUCss0-24h prediction 
The level of agreement between AUCssTest: 0-24h and AUCssRef: 0-24h for obese (N=56) and non-obese 
(N=82) individuals for all limited sampling strategies combined can be observed in Figure 3.4 through 3.7. 
Figure 3.6 and Figure 3.7 compare AUCssTest: 0-24h versus AUCssRef: 0-24h for obese and non-obese individuals 
respectively. Figure 3.8 and Figure 3.9 are Bland-Altman plots representing the overall agreement between 
AUCssTest 0-24h and AUCssRef: 0-24h for obese and non-obese individuals respectively. 
 




Figure 3.7: AUCssTest: 0-24h versus AUCssRef: 0-24h for non-obese individuals stratified by limited sampling strategy. Red line is the 





Figure 3.8: Bland-Altman plot representing overall agreement between AUCssTest: 0-24h and AUCssRef: 0-24h by limited sampling 
strategy for obese individuals, solid blue line represents mean difference between AUCssTest: 0-24h and AUCssRef: 0-24h and dashed 




Figure 3.9: Bland-Altman plot representing overall agreement between AUCssTest: 0-24h and AUCssRef: 0-24h by limited sampling 
strategy for non-obese individuals, solid blue line represents mean difference between AUCssTest: 0-24h and AUCssRef: 0-24h and 




Figure 3.10: Prediction error of the AUCssTest: 0-24h estimate with each limited sampling strategy stratified by obesity status. Each 
box represents the median, 25th and 75th percentile of the prediction error and whiskers extend to the value no further than 1.5 
times the interquartile range. Points indicate potential outliers. 
Figures 3.4 to 3.10 suggest that obesity status influences the predictive performance of the limited 
sampling strategies tested. For the obese group, all limited sampling strategies resulted in a negatively 
biased AUCssRef: 0-24h. In the non-obese group, several sampling strategies resulted in unbiased estimates of 
AUCssRef: 0-24h: dose 1 Cmin, dose 2 Cmin, doses 2 and 3 Cmins, dose 1 Cmax and Cmin and dose 2 Cmax and Cmin. 
The non-obese group also showed lower imprecision compared to the obese group. 
Figures 3.11 to 3.13 depict the relative difference between values of AUCssTest: 0-24h and AUCssRef: 0-
24h stratified by both obesity status and sampling strategy. These plots demonstrate how the value of 
AUCssTest: 0-24h was underestimated to a greater extent and with greater distribution in obese individuals 




Figure 3.11: Relative difference plot depicting the difference of AUCssTest 0-24h and AUCssRef: 0-24h by limited sampling strategy for 
obese individuals, solid blue line represents mean relative difference between AUCssTest: 0-24h and AUCssRef: 0-24h and dashed 




Figure 3.12 Relative difference plot depicting the difference of AUCssTest 0-24h and AUCssRef: 0-24h by limited sampling strategy for 
non-obese individuals, solid blue line represents mean relative difference between AUCssTest: 0-24h and AUCssRef: 0-24h and dashed 




Figure 3.13: Relative prediction error (%) of the AUCssTest: 0-24h estimate with each limited sampling strategy stratified by obesity 
status. Each box represents the median, 25th and 75th percentile of the prediction error and whiskers extend to the value no further 
than 1.5 times the interquartile range. Points indicate potential outliers. 
A difference in AUCssTest: 0-24h/AUCssRef: 0-24h was found between these obese and non-obese 
groups. For the non-obese group, all limited sampling strategies resulted in a ratio that met the 
bioequivalence criteria. A significant difference in P20 was found between the nine limited sampling 
strategies (Cochran’s Q (8) = 79; p<0.001). Post hoc analysis determined he most accurate was from the 
limited sampling strategy using the dose 5 Cmin (P20 84%, 95% CI 74-91%) though this was only 
statistically significantly greater than the dose 1 Cmin (66% 95% CI 55-76%; p <0.05) and the dose 1 Cmax 
and Cmin (65% 95% CI 53-75%; p <0.05); no other significant differences in P20 were found. The full list 
of pairwise comparisons for the non-obese group is available in Appendix 5.5. For the obese group, none 
of the limited sampling strategies implemented met the bioequivalence criteria, therefore no comparisons 
for P20 were undertaken. Metrics of bias, equivalence and P20 by obesity status and limited sampling 
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Table 3.6: Results of mean absolute bias (95% CI), AUCssTest: 0-24h/AUCssRef: 0-24h geometric mean (90% CI) and P20 (95% CI) for obese and non-obese sub-groups. * represents 
that the AUCssTest :0-24h/AUCssRef: 0-24h meets the low therapeutic index bioequivalence range 
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 Factors that contribute to bias in prediction error 
The results of the multilinear regression model are presented in Table 3.7 which predicted that an 
individual with a higher BMI would result in an underestimation and being of “Other” descent would result 
in an overestimation of AUCssRef: 0-24h. All other variables were deemed to be non-significant. This model 
has an adjusted R2 value of 0.18 and diagnostic plots for the model can be found in Appendix 5.6.1. 
Parameter Coefficient p-value 
Constant -61.19 (-82.39, -39.99) < 0.001 
Body mass index (kg/m2) -4.50 (-7.06, -1.94) <0.001 
Ethnicity: Māori -17.16 (-100.21, 65.88) 0.683 
Ethnicity: Pacific Islander -42.29 (-140.68, 56.09) 0.397 
Ethnicity: Other 98.16 (26.12, 170.21) 0.008 
Table 3.7 Coefficients of multilinear regression model for prediction error to all patient covariates. Model has been centred and 
simplified with Akaike Information Criteria. ‘Constant’ represents the mean of the prediction error for an individual when all 
parameters are at their mean or reference value and represents the average prediction error (mg.h/L). Coefficients represent 
change in the prediction error (mg.h/L) with 95% CIs. P values indicate whether the parameter is considered significant to the 




4 Discussion and conclusion 
 Summary of findings 
The principle finding of the present study of vancomycin was that a limited sampling strategy using 
one to two Cmin or combinations of Cmax and Cmin concentrations resulted in a negatively biased estimate of 
AUCss0-24h. This bias was supported by the finding that all strategies (except the Cmin for doses 2 and 3) did 
not meet the narrow bioequivalence criterion of 0.90-1.11. For the only strategy that fulfilled narrow 
bioequivalence (Cmin for doses 2 and 3), it was predicted that BMI and an ethnicity of “Other” was predicted 
to affect bias. Stratification by obesity status identified that estimates were biased in obese individuals, but 
not in non-obese individuals. In addition, none of the limited sampling strategies produced an AUC ratio in 
obese individuals that was within the bioequivalence range whereas all limited sampling strategies met the 
bioequivalence criteria for the non-obese group; the P20 for the non-obese group varied from 65% to 84%. 
Therefore, the present study found that limited sampling strategies were able to estimate AUCss0-24h with 
minimal bias, but only in non-obese individuals. 
 The findings in relation to other work 
To date, only a few published studies have investigated whether a limited sampling strategy can 
accurately estimate vancomycin AUCss0-24h using Bayesian dose forecasting. Of these studies, the 
following aspects of methodology have varied; 1) the prior model implemented, 2) the software used (with 
potential different implementations of the Bayesian search algorithm), 3) the investigative population, and 
4) the limited sampling strategies tested. Only two studies have looked at the implementation of the 
Thomson et al. model (2). Turner et al. (58) found the sampling strategies of Cmin as well as Cmax and Cmin 
significantly underestimated AUCssTest: 0-24h. While the mean prediction error was not explicitly stated, 
values of AUCssTest: 0-24h/AUCssRef: 0-24h indicated bias (Cmin only: 0.84 (interquartile range 0.77-0.88), Cmax 
and Cmin: 0.88 (interquartile range 0.83-0.92)). While this review had the Thomson et al. model (2) 
implemented, it was completed on patients in an intensive care unit and with 5 days of sample data rather 
than one to two sample concentrations, i.e., even with more sample data the investigators found significant 
bias. Shingde et al. (59) demonstrated that the value of AUC0-∞ was able to be predicted with no significant 
bias using one sample, but comparison to this is also difficult as this study was focussed on the ideal 
sampling time after the infusion and used a different outcome metric to that used in the present study. 
The data on limited sampling strategies in obese individuals is more scant; none have reviewed the 
accuracy of the Thomson et al. (2) model with an obese population. The difference in response between 
obese and non-obese individuals observed in the present study could be attributed to a poor fit between the 
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population used to create the model and the included individuals, particularly those in the obese group. The 
prior model implemented estimated vancomycin clearance from CLcr based on total body weight. This is 
because Thomson et al (2) found other weight metrics (lean or ideal body weight) did not provide clear 
improvements in the model fit compared to using total body weight. The proportion of obese individuals in 
the present study (41%) is much greater than in the prior model (19%). It is possible that this difference 
could be a factor in the high levels of prediction error seen in this group; individuals with a higher total 
body weight may have a disproportionally higher CLcr which would correlate to a higher estimation of 
vancomycin clearance. This could result in an underestimation of AUCss0-24h. This potential discrepancy in 
vancomycin clearance combined with the limited number of samples used in the implemented strategies 
would mean that the MAP produced estimates rely heavily on the prior model; a poor match could result in 
biased estimates. 
It has been suggested from literature that the addition of a Cmax value increases accuracy in obese 
individuals (62, 63). The present study demonstrated that despite the addition of the Cmax, the estimate was 
still significantly biased. This contrasts with results seen in the literature which has found that the estimate 
of AUCss0-24h improves significantly with the addition of a “peak” (Cmax or value taken a specified time 
after the infusion). Carreno et al. (62) found that using Cmin values only was not accurate enough to estimate 
AUCss0-24h (AUCssTest: 0-24h/AUCssRef: 0-24h range of 0.87 (95% CI 0.77-0.97) to 1.30 (95% CI 1.19-1.40)), 
but the inclusion of a “peak” sample (taken 1 hour post infusion) improved estimates (AUCssTest: 0-
24h/AUCssRef: 0-24h 0.91 (95% CI 0.87-0.95) to 0.99 (95% CI 0.94-1.04)). The difference seen between the 
present study and that by Carreno et al. could be explained by the study methodology, in particular the prior 
models used (as Carreno did not evaluate the Thomson et al. (2) model) and that they used more samples 
than the present study, Carreno et al. used five for each patient. It could be expected that fewer available 
concentrations mean more reliance on the Bayesian prior for predictions, this could lead to a biased 
estimation of AUCssTest: 0-24h if the prior model does not match the population well. Two patient variables 




 Limitations of the present study 
 Limited sampling strategies implemented 
The present study implemented nine specific limited sampling strategies which were selected to 
align with current clinical workflows and observe whether early whether the numbered dose affected the 
estimate. There are numerous more permutations that could be used. Since the accuracy of the Bayesian 
search algorithm improves with more individual samples, it is likely that adding more samples would 
increase the accuracy seen compared to the present study. By using at most two samples, the predictions 
seen rely heavily on the prior model. Certain combinations may be able to predict an unbiased AUCss0-24h, 
particularly in obese individuals who did not fare well in the present study. 
Another limitation with regards to the limited sampling strategies was the sampling times used. 
The value of Cmax was determined as the maximal simulated concentration for a given dose, the time of 
which after the infusion initiation varied depending on the dose administered as the infusion time varied. 
The value of Cmin was the minimum simulated sample concentration. These values, while explicit, would 
be hard to replicate in clinical practice, but a definition was required to be able to estimate AUCssTest: 0-24h. 
Other groups have determined Cmin by similar strategies, and it would not be expected that the value of Cmin 
would drastically change over the few hours prior to the end of the dose period. Conversely, the definition 
of Cmax or peak varies in literature but often relates to a specified time after the infusion ends. Varying the 
sampling time used would identify any significant issues related to workflows that would likely match 
clinical practice. 
 Simulation methodology 
This study was a simulation study that used data from an existing dataset (demographic and dosing 
strategies) to simulate the expected response. This simulation study did not use actual vancomycin 
concentrations to inform the Bayesian conditional posterior, rather it used the simulated plasma 
concentrations. Vancomycin plasma levels are affected by inter- and intra-individual variability; while 
NONMEM predicted that an individual would respond a certain way to a dosing regimen, it is possible that 
an individual in reality reacts completely differently. 
The present study’s methodology compared the P20 between results using pairwise McNemar tests 
and p-values were adjusted for multiple comparisons using the Bonferroni correction. As this correction is 
rather conservative, especially with correlated results, the chance of observing a type II error (which would 
result in a non-significant difference in error) is increased. 
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Finally, for the present study, no patient was considered for exclusion due to being an outlier. These 
patients were kept in the study to see how the methods fared with the complete eligible dataset. 
Additionally, the regression curves were not a large contributor of the main findings. This means that there 
is a potential of including patients who did not fit the prior population model well and potentially 
influencing the results. 
 Patient population 
The patient population of the present study was taken from an existing dataset collated by the 
Clinical pharmacology department at the CDHB. This dataset is informed by the ePA implemented which 
is used in all inpatient areas except the emergency department and intensive care unit. Since the present 
study excluded: adults who were in ICU, had CLcr > 30 mL/min and as the simulation methodology 
assumed that an individual was clinically stable across the duration of therapy, the results of the present 
study may not be applicable to all hospitalised individuals. 
 Prior model used 
The prior model implemented is a well-known two-compartmental model. As previously discussed, 
the significant bias seen (particularly in obese individuals) may be due to a poor fit between this cohort and 
the prior model, potentially due to the way that the model estimates clearance. The best estimation of renal 
function in obese individuals is heavily debated but using total body weight is likely to overestimate CLcr. 
Other metrics such as fat free mass or ideal body weight can be used in lieu of total body weight which may 
reduce this bias seen. Additionally, there are several other pharmacokinetic models available for 
vancomycin (60) including ones derived from obese populations (65), one may prove to estimate AUCss0-
24h with less bias. Uster et al. (66) recently demonstrated that it is possible to average several diverse models 
as well as use selection algorithms to determine the best model (or average of models) for an individual. 
Otherwise, it is possible to produce a pharmacokinetic model from an existing population (e.g., the obese 
individuals in the ChCh TDM dataset) and use this as the prior model. 
 Implications for clinical practice 
The monitoring strategy for vancomycin has evolved over the decades it has been in clinical use 
(3). the most recent evidence has pointed to using the pharmacokinetic/pharmacodynamic metric, 
AUC24/MICBMD (4, 7, 8, 38, 42-45). There are several methods of estimating AUCss0-24h but Bayesian 
forecasting techniques using specialised software has been shown to be effective and simple. Since the 
monitoring of vancomycin by Cmin concentrations has been so well ingrained into clinical practice, a simple 
and accurate method of converting a limited sampling strategy to AUCss0-24h is needed. The present study 
is novel in that it investigates the utility of Bayesian dose forecasting with a known prior model and using 
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sampling strategies that align with current clinical workflows at CDHB. The test strategies chosen for the 
present study were to align with existing clinical workflows and to see whether the estimated AUCss0-24h 
from each could be used clinically and were early enough in the treatment course that the rapid attainment 
of the therapeutic range could be achieved. 
A major consideration for clinical practice is whether the estimate is “accurate enough”. The 
bioequivalence range chosen to equate AUCssTest: 0-24h to AUCssRef: 0-24h with greater assurance than the 
standard bioequivalence range of 0.80-1.25; this is important with narrow therapeutic range drugs such as 
vancomycin. The range used in the present study meant that the AUCssTest: 0-24h could vary from 360-
444 mg.h/L when the AUCssRef: 0-24h is 400 mg.h/L and from 540-666 mg.h/L when the AUCssRef: 0-24h is 
600 mg.h/L and still be considered equivalent. This difference is unlikely to be of clinical significance, 
especially in the context of the vancomycin assay having measurement error of similar magnitudes (intra-
and inter-day CV of 5-10% (E Barnes, Canterbury Health Laboratories, personal communication 2021)). 
The present study showed that several of the AUCssTest: 0-24h were biased, specifically that they 
underestimated AUCssRef: 0-24h. For underestimates, the primary concern is underestimating values of 
AUCss0-24h at the upper end of the therapeutic range; if the “true” value of AUCss0-24h was higher that 
estimated, doses may not be adjusted when necessary. Since the mean value of AUCssRef: 0-24h was close to 
600 mg.h/L, it is possible to evaluate this theoretical risk. For example, for the whole study population, the 
only limited sampling strategy that met the bioequivalence criteria was using the Cmin from doses 2 and 3 
(0.927, 90% CI 0.902-0.953); i.e., it underestimated AUCssTest: 0-24h by approximately 7% which correlated 
to a mean prediction error of -56.20 mg.h/L (95% CI -77.00- -35.39 mg.h/L). Since a difference in AUCss0-
24h of -77 mg.h/L is unlikely warrant a dose change in the setting of an AUCss0-24h of around 600 mg.h/L, 
this difference would not be considered clinically significant. 
Another consideration in clinical practice is the practicality of the sampling strategy. Ideally, 
samples should be taken as close to treatment initiation as possible and with as few samples as possible. 
That way, clinicians can identify early in the course whether a specific dose is therapeutic or toxic, before 
harm occurs. Obtaining plasma samples from an individual is an invasive and time-consuming process. By 
using a limited sampling strategy (especially with one sample) these negative aspects are minimised. 
Overall, the present study demonstrated that it is possible to estimate AUCss0-24h using certain 
limited sampling strategies and a MAP estimator with a level of bias that would be clinically acceptable, 
though only for the non-obese group. As it is desirable to monitor early in the treatment course and with as 
few samples as possible, the present study provides evidence that for non-obese individuals, using the Cmin 
of dose 2 provides an estimate that is not statistically different from ones obtained later in the treatment 
course or that use two plasma samples. While the dose 1 Cmin did meet the bioequivalence range, the 
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resulting P20 was significantly lower than from other limited sampling strategies. The present study does 
not demonstrate that these techniques can be used in obese individuals, even with two samples, due to the 
bias seen. Further research in this group is needed to identify the strategies required to produce an estimate 
that can be clinically used. 
 Future directions 
Future research is needed to expand on the results seen in the present study. The present study 
focussed on nine specific limited sampling strategies for their accuracy. Firstly, there are many 
permutations of sample concentrations that could be tested for their accuracy in estimating AUCss0-24h, 
either as a single concentration or multiple concentrations, e.g., using the dose 1 Cmax and Cmin and another 
Cmin concentration may provide enough information for obese individuals. Secondly, the timing of the 
samples could be adjusted and not be specifically Cmax or Cmin. Shingde et al (59) found, samples taken mid-
profile might be more accurate than Cmin values. By adjusting either 1) the dose(s) sampled and 2) the time 
of the sample it is possible that a combination is found that is accurate for both obese and non-obese 
individuals and can provide this estimate early enough in the course to be of clinical benefit. 
A review of the prior model used for obese individuals is warranted. There is a paucity of data in 
this area, but it appears that a pharmacokinetic model derived from obese individuals performs with 
moderate accuracy in obese individuals. It would be possible to generate pharmacokinetic prior estimates 
from the obese cohort in the ChCh TDM dataset and see if this prior model performs better, or to use an 
existing pharmacokinetic model derived from obese individuals (65). Recent work (66) has demonstrated 
that algorithms that average models or select specific models based on the individual might improve 
predictions, including in obese individuals. A concept not discussed in recent literature is that of a feedback 
prior model. This is where the prior model estimates are adjusted based on the Bayesian conditional 
posterior. This constant feedback means that the initial estimates for an individual are an amalgamation of 
the original prior model as well as the local cohort of patients being treated. This would mean that a 
reputable prior model could be initially implemented and constantly adjusted based on the local population. 
Another strategy would be to estimate CLcr in the ChCh TDM dataset using a different metric for weight 
(e.g., ideal body weight or fat free mass) as these methods may provide a more accurate estimate of 
vancomycin clearance. In addition to this, evaluation of further pharmacokinetic models (regardless of 
obesity status) could be considered to enhance this work. 
This research investigated the accuracy of converting a limited sampling strategy to an AUCss0-24h 
but did not compare this to other methods of estimating AUCss0-24h. To investigate the clinical utility of the 
sampling strategies investigated in this research, further research could compare the results obtained from 
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the methodology in this research to that obtained by targeting Cmin concentrations as well as from empirical 
estimates. While other groups have done similar research, validating the techniques in a local population 
could confirm that the extra time to get the result from Bayesian techniques provided important 




In conclusion, the present study found that a limited sampling strategy using a Bayesian dose 
forecasting significantly underestimated AUCss0-24h when using limited sampling strategies. Stratification 
by obesity status found a difference in precision error between obese and non-obese individuals. In obese 
individuals, none of the limited sampling strategies implemented produced an estimate of AUCss0-24h that 
was unbiased nor that met the bioequivalence criteria. Conversely, several limited sampling strategies for 
non-obese individuals were not biased: dose 1 Cmin, dose 2 Cmin, dose 2 and 3 Cmin, dose 1 Cmax and Cmin 
and dose 2 Cmax and Cmin; all sampling strategies met the bioequivalence criteria in this group. As it is 
preferred that as few samples are taken as needed and that this occurs early in the course, the present study 
provides evidence that clinicians could use a single Cmin to estimate AUCss0-24h for non-obese individuals, 
preferably earlier in the course (e.g., dose 2 or 3). For obese individuals, further research is needed to find 




Appendix 5.1: Data manipulation and calculation of AUCssRef: 0-24h 
Appendix 5.1.1: Manual data manipulation 
Before any scripted execution, manual data manipulation was needed: 
• Individual 19 - removal of test “(Prisma, in ICU)” from dialysis details 
• Individuals: 33, 78, 79, 80, 83, 84, 85, 86, 87, 88, 93, 104, 116, 117, 160 ,161, 162, 163, 
164, 165, 1655, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 
183, 184 - change “No” to “N” in dialysis details 
• Individual 152 - change “M” to “N” in dialysis detail 
• Individual 74 had the datetime and “dose 4” shifted once cell right so this was manually 
adjusted 
• Ethnicity was determined by the ethnicity recorded in the column “Ethnicity 1” and was 
grouped to: NZ European/Pākehā, Māori, Pacific Islander and Other 
• Individual 153 had their weight recorded as 999kg, this was changed to NA 









# Cockroft-Gault function  
crcl = function(weight, age, scr, sex){ 
  if(sex == 1){ 
    return(((140-age)* weight)/(scr * 0.8)) 
  } else { 
    return((((140-age)* weight)/(scr * 0.8)*0.85)) 
  } 
} 
data_all = read_excel("./data/data_original.xlsx") 
 
 
data = data_all %>% rowwise() %>% 
  mutate( 
    id = `Baseline variables_ID`, 
    ethnicity = `Ethnicity 1`, 
    age = round(age, digits=0), 
    sex = as.factor(Sex), 
    height = `Height (cm)`, 
    weight_tbw = `Dose 1 weight (kg)`, 
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    bmi = weight_tbw/((height/100)^2), 
    is_obese = factor(bmi >= 30), 
    dose1_amt = as.integer(`Dose 1 amount (mg)`), 
    dose1_scr = as.integer(`Dose 1 creatinine (umol/L)`), 
    dose1_mg_kg = dose1_amt/weight_tbw, 
    dose2_amt = as.integer(`Dose 2 amount (mg)`), 
    dose2_scr = as.integer(`Dose 2 creatinine (umol/L)`), 
    dose2_mg_kg = dose2_amt/weight_tbw, 
    dose3_amt = as.integer(`Dose 3 amount (mg)`), 
    dose3_scr = as.integer(`Dose 3 creatinine (umol/L)`), 
    dose3_mg_kg = dose3_amt/weight_tbw, 
    dose4_amt = as.integer(`Dose 4 amount (mg)`), 
    dose4_scr = as.integer(`Dose 4 creatinine (umol/L)`), 
    dose4_mg_kg = dose4_amt/weight_tbw, 
    dose5_amt = as.integer(`Dose 5 amount (mg)`), 
    dose5_scr = as.integer(`Dose 5 creatinine (umol/L)`), 
    dose5_mg_kg = dose5_amt/weight_tbw, 
    maintenance_tau = 24/`Prescription 2 number of doses per 24 hours`, 
    dialysis = as.factor(`On dialysis?`), 
    crcl_tbw = crcl(weight=weight_tbw, age=age, scr=dose1_scr, sex=sex) 
  ) %>% select( 
    id,  age, 
    sex, height, weight_tbw,  
    bmi,ethnicity, crcl_tbw, 
    dose1_amt, dose2_amt, dose3_amt, dose4_amt, dose5_amt, 
    dose1_scr, dose2_scr, dose3_scr,dose4_scr, dose5_scr, 
    dose1_mg_kg, dose2_mg_kg, dose3_mg_kg, dose4_mg_kg, dose5_mg_kg, 
    maintenance_tau, dialysis, is_obese 
  ) %>%  
  var_labels( 
    sex = "Sex", 
    ethnicity = "Ethnicity", 
    height = "Height (cm)", 
    age = "Age (years)", 
    weight_tbw = "Total body weight (kg)", 
    crcl_tbw = "Creatinine clearance (mL/min)", 
    bmi = "Body mass index (kg/m^2)", 
    dose1_amt = "Dose 1 amount (mg)", 
    dose2_amt = "Dose 2 amount (mg)", 
    dose3_amt = "Dose 3 amount (mg)", 
    dose4_amt = "Dose 4 amount (mg)", 
    dose5_amt = "Dose 5 amount (mg)", 
    dose1_scr = "Serum creatinine at dose 1 (umol/L)", 
    dose2_scr = "Serum creatinine at dose 2 (umol/L)", 
    dose3_scr = "Serum creatinine at dose 3 (umol/L)", 
    dose4_scr = "Serum creatinine at dose 4 (umol/L)", 
    dose5_scr = "Serum creatinine at dose 5 (umol/L)", 
    dose1_mg_kg = "Dose 1 mg/kg", 
    dose2_mg_kg = "Dose 2 mg/kg", 
    dose3_mg_kg = "Dose 3 mg/kg", 
    dose4_mg_kg = "Dose 4 mg/kg", 
    dose5_mg_kg = "Dose 5 mg/kg", 
    maintenance_tau = "Frequency of maintenance dose (hr)", 
    dialysis = "Patient on dialysis", 
    is_obese = "Patient is obese" 
  ) 
 
# Changing all "0" results to NA 
data = na_if(data, 0) 
data = na_if(data, NaN) 
data = na_if(data, Inf) 
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data = na_if(data, "NaN") 
 
data = data %>% 
  mutate( 
    sex = sjmisc::rec(sex, rec = "Male,M=M; F=F") 
  ) 
Appendix 5.1.2: Exclusion of individuals 
excluded_subjects = data %>%  
  filter( 
    dialysis == "Y" |  
    is.na(dialysis) | 
    is.na(age) |  
    is.na(dose2_amt) | 
    is.infinite(maintenance_tau) | 
    is.na(height) |  
    is.na(weight_tbw)  
    |  crcl_tbw < 30 
    ) %>% 
  mutate( 
    dialysis = as.logical(dialysis != "N" | is.na(dialysis)), 
    age_wrong = as.logical(is.na(age)), 
    no_height = as.logical(is.na(height)), 
    no_weight = as.logical(is.na(weight_tbw)), 
    no_maintenance_dose = as.logical(is.na(dose2_amt)|is.infinite(maintenance_tau)), 
    no_scr = as.logical(is.na(dose1_scr)), 
    renal_function = as.logical(crcl_tbw < 30) 
  ) 
 
# removing the "excluded_subjects" from the original data frame and reassigning 
included_subjects = data[ 
  !data_all$`Baseline variables_ID` %in% excluded_subjects$id,  
  ] %>% mutate ( 
    id = as.integer(gsub("^VAN", "", id)) 
    ) 
 
excluded_subjects %<>% mutate( 
  id = as.integer(gsub("^VAN", "", id) 
  ) 
) 
write_rds(included_subjects, "./data/included_subjects.rds") 
write.csv(included_subjects, "./data/included_subjects.csv", row.names = FALSE) 
write_rds(excluded_subjects, "./data/excluded_subjects.rds") 
write.csv(excluded_subjects, "./data/excluded_subjects.csv", row.names = FALSE) 
Appendix 5.1.3: Generation of NONMEM file 
A file had to be produced in a specific format so that NONMEM could estimate concentration 
values for each timestamp (which could then be used to estimate AUCssRef: 0-24h). 
get_dose_recursive = function(doses, dose_number){ 
  # Function to recursively get the dose amount (mg) that corresponds to the  
  # dose number 
  # If there is no dose recorded, it will grab the most recent dose amount 
  # e.g. given 1500mg, 1000mg, 1250mg, NA, NA will report as for first three, 
  # then continue 1250mg to completion 
   
  # First, as there are max 5 doses recorded, don't let this count > 5 
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  # Recursive case will catch this but this is faster 
  if (dose_number > 5) { 
    return(get_dose_recursive(doses, 5)) 
  } 
   
  # base case 1:  every patient has a dose number 2 
  if (dose_number == 2){ 
    return(doses[[2]]) 
  # Base case 2: there is a dose recorded for that dose number 
  } else if (!is.na(doses[1, dose_number][[1]])) { 
      return(doses[1, dose_number][[1]]) 
     
  # Recursive case: no dose exists for that dose number, return the result 
  # of calling the function with the previous dose number 
  } else { 
      return(get_dose_recursive(doses, dose_number - 1)) 
  } 
} 
nonmem = function(df){ 
  # in this instance df is the `included_subjects` dataframe but this 
  # allows a copy to be made for NONMEM 
  res = data.frame() 
  for(row in 1:nrow(df)){ 
    maintenance_tau = df[row, "maintenance_tau"][[1]] 
    doses = df[ 
      row, c("dose1_amt", "dose2_amt", "dose3_amt",  
             "dose4_amt", "dose5_amt")] 
    age = df[row, "age"][[1]] 
    sex = ifelse(df[row, "sex"][[1]] == "M", 1, 0) 
    bmi = df[row, "bmi"] 
    WTKG = df[row, "weight_tbw"][[1]] 
     
    # the next is calculated from baseline SCr 
    CLCRWT = crcl(WTKG, age, df[row, "dose1_scr"][[1]], sex) 
 
    # initializing with the loading dose 
    temp = data.frame( 
      "#ID" = df[row, "id"][[1]], 
      TIME = 0, 
      AMT = doses[[1]], 
      RATE = 500, 
      DVID = 0, 
      DV = ".", 
      MDV = 1, 
      AGE = age, 
      SEX = sex, 
      WTKG = WTKG, 
      CLCRWT = CLCRWT, 
      "BMI" = bmi 
    ) 
    # Next, we need to generate 264 lines - 1 per hour (0-263) per patient and  
    # group that back to the main result 
    # we also need to add in another row if the maintenance tau falls on that  
    # hour corresponding to the dose 
     
    for(time in 0:263) { 
      # First, add in the row for the hour 
      temp = rbind( 
        temp, 
        data.frame( 
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          "#ID" = df[row, "id"][[1]], 
          TIME = time, 
          AMT = 0, 
          RATE = 0, 
          DVID = 1, 
          DV = "", 
          MDV = 0, 
          AGE = age, 
          SEX = sex, 
          WTKG = WTKG, 
          CLCRWT = CLCRWT, 
          "BMI" = bmi 
        ) 
      ) 
       
      # Next, check for whether it's a dose interval time and if so, 
      # add an extra row with that info 
      if(time %% maintenance_tau == 0 & time != 0){ 
        temp = rbind( 
          temp,  
          data.frame( 
            "#ID" = df[row, "id"][[1]], 
            TIME = time,  
            AMT = get_dose_recursive(doses, (time/maintenance_tau)+1), 
            RATE = 500, 
            DVID = 0, 
            DV = ".", 
            MDV = 1, 
            AGE = age, 
            SEX = sex, 
            WTKG = WTKG, 
            CLCRWT = CLCRWT, 
            "BMI" = bmi 
          ) 
        ) 
      } 
    } 
     
    #At the end of each patient, bind it back to the result 
     
    res = rbind(res, temp) 
    res = remove_all_labels(res) 
  } 
  return (res) 
} 
 
nonmem_data_all = nonmem(included_subjects) 
write.csv(nonmem_data_all, "./data/nonmem_data.csv", row.names = FALSE) 
This file was then used in NONMEM (using the MAP estimator and the pharmacokinetic model). 
NOMEM added the following parameters: 𝐶𝐿, 𝑉1, 𝑉2, 𝑄 and vancomycin concentration at each time point. 
Appendix 5.1.4: AUCssRef: 0-24h calculation 
AUCssRef: 0-24h for each patient was determined using the function AUC from the Noncompart 
package. The final reference results were saved to a CSV file under a single column against the individuals 
ID, nine other columns were generated to be filled in with TCIWorks data. 
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get_auc = function(id, day){ 
  # Function to get the AUC 
  # params: 
  #     id: subject's ID 
  #     day: integer representation of the day 
  # Returns a single number - the AUC for the previous 24 hours 
 
  end_hour = 24 * day 
  start_hour = end_hour - 24 
   
  conc_time = nonmem_data_MAP %>% filter( 
    ID == id & `Time(hr)` >= start_hour & `Time(hr)` <= end_hour 
    ) %>% select( 
      `Vanco conc [REF] mg/L`, `Time(hr)` 
    ) 
  colnames(conc_time) = c("conc", "time") 
  conc_time = conc_time[!duplicated(conc_time$time),] 
   
  # The AUC function requires two vectors, x (time) and y (concentration) 
  auc = NonCompart::AUC(conc_time$time, conc_time$conc, down="Linear") 
   
  # This results in the cumulative AUC for each time stamp. I only need the  
  # last one for each call of this function 
  return(tail(auc, n=1)[[1]]) 
} 
 
# Finally, to create the data frame where each row is the id + AUC data 
auc_data = included_subjects %>% rowwise %>% mutate( 
  auc10 = get_auc(id, 10), 
  nothing = NA, 
  AUCt1 = NA, 
  AUCt2 = NA,  
  AUCt3 = NA, 
  AUCt4 = NA, 
  AUCt5 = NA, 
  AUCt2_3 = NA, 
  AUCp_t1 = NA, 
  AUCp_t2 = NA 
) %>% 
  var_labels( 
    auc10 = "AUCss day 10", 
    nothing = "No concentration data in TCIWorks", 
    AUCt1 = "AUCssTest: 0-24h with dose 1 Cmin", 
    AUCt2 = "AUCssTest: 0-24h with dose 2 Cmin", 
    AUCt3 = "AUCssTest: 0-24h with dose 3 Cmin", 
    AUCt4 = "AUCssTest: 0-24h with dose 4 Cmin", 
    AUCt5 = "AUCssTest: 0-24h with dose 5 Cmin", 
    AUCt2_3 = "AUCssTest: 0-24h with doses 2 and 3 Cmin", 
    AUCp_t1 = "AUCssTest: 0-24h with Cmax/Cmin on dose 1", 
    AUCp_t2 = "AUCssTest: 0-24h with Cmax/Cmin on dose 2" 
  ) 
 
write.csv(auc_data, "./data/reference_auc_data_template.csv", row.names=FALSE) 
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Appendix 5.2: TCIWorks data entry and calculation of AUCssTest: 0-24h 
TCIWorks (version 1.0-RC1) was installed on a Windows 7 virtual machine using Oracle 
VirtualBox (version 6.1.18 r142142). Python (version 3.8.8) was also installed locally on the machine. Two 
separate Python scripts were written and run to: 
1. Enter patient data by manipulating the TCIWorks graphical user interface (GUI) 
2. Calculate the AUCssTest: 0-24h from the resulting “Course Report” functionality in TCIWorks 
Appendix 5.2.1: TCIWorks setup 
 
Figure 5.1: Implementation of the Thomson et al. (2) pharmacokinetic model in TCIWorks. 
Appendix 5.2.2: Packages and Dependencies 
Several Python packages and dependencies were required: 
• et-xmlfile version 1.0.1 
• jdcal version 1.4.1 
• MouseInfo version 0.1.3 
• Numpy version 1.20.1 
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• Openpyxl version 3.0.6 
• Pandas version 1.2.3 
• Pillow version 8.1.2 
• PyAutoGUI version 9.52 
• PyGetWindow version 0.0.9 
• PyMsgBox version 1.0.9 
• Pyperclip version 1.8.2 
• PyRect version 0.1.4 
• PyScreeze version 0.1.26 
• python-dateutil version 2.8.1 
• PyTweening version 1.0.3 
• Pytz version 2021.1 
• Six version 1.15.0 
Appendix 5.2.3: TCIWorks automated data entry 
The following code was used to automate the data entry of patient demographics, course details 
and simulated sample concentrations into TCIWorks to produce a “Course Report” for each individual-
limited sampling strategy combination and save the output as a comma separated variable (CSV) file. Each 
course was started on 1/1/21 so that AUCssTest: 0-24h would always be on 10/1/21. Figure 5.2 demonstrates 
the addition of the course details for subject 1. 
 
import pyautogui 
import pygetwindow as gw 
import time 
from progress.bar import ChargingBar 
import pandas as pd 
import datetime 
from datetime import timedelta 
 
 
def main(skip, create, course): 
        """ 
        Skip: ID to skip past 
        Create: Boolean to create patients 
        Course: Boolean to add course data 
        :return:None 
        """ 
 
    # load the file and initialise the dictionary 
    print("Loading file 1...") 
    data = pd.read_excel(r"./data/1_REFDATA_vancoChCh_FINAL3.xlsx") 
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    nonmem_df = pd.DataFrame(data, columns=["ID", "Time(hr)", "Vanco conc [REF] 
mg/L", "Dose (mg)", "AGE", "SEX", "WTKG"]) 
    print("Loading file 2...") 
 
    global included_subjects 
    included_subjects = pd.read_csv(r"./data/included_subjects.csv") 
    df_subjects = pd.DataFrame(included_subjects, columns=["id", "age", "sex", 
"height", "weight_tbw", "dose1_scr"]) 
    data = load_data(nonmem_df, df_subjects) 
    enter_into_tciworks(data, skip=skip, create=create, course=course) 
 
 
def load_data(nonmem_df, df_subjects): 
    """ 
    Load the relevant data from the NONMEM file 
    Needs information on maintenance tau from "included_subjects.csv" to 
determine time 
        returns: dictionary with the following structure: 
            { 
                id:{ 
                    patient_details : { 
                        surname, 
                        first_name, 
                        age, 
                        sex, 
                        height, 
                        weight, 
                        scr 
                    }, 
                    course_details : [ 
                        {amt, time}, 
                        {amt, time}, 
                        ... 
                    ], 
                    dose1_Cmax:   {concentration, datetime}, 
                    dose1_Cmin: {concentration, datetime}, 
                    dose2_Cmax:   {concentration, datetime}, 
                    dose2_Cmin: {concentration, datetime}, 
                    dose3_Cmin: {concentration, datetime}, 
                    dose4_Cmin: {concentration, datetime}, 
                    dose5_Cmin: {concentration, datetime} 
                } 
            } 
    """ 
 
    # Few helper functions 
    def get_dose_Cmax(patient_id, dose): 
        """ 
        function to get the concentration/time of a designated Cmax 
        returns a dictionary with a concentration and string representation of 
the date 
        """ 
        # Convert the id and dose into a time range 
        maintenance_tau = int(included_subjects[included_subjects["id"] == 
patient_id]["maintenance_tau"]) 
        dose_start_time = (dose - 1) * maintenance_tau 




        # Subset the main dataframe to get the single dose profile 
        dose_profile = nonmem_df[ 
            (nonmem_df["ID"] == patient_id) & (nonmem_df["Time(hr)"] <= 
dose_end_time) & (nonmem_df["Time(hr)"] >= dose_start_time)] 
        # Extract the row where the conc is maximal 
        cmax = dose_profile.iloc[[dose_profile["Vanco conc [REF] 
mg/L"].argmax()]] 
        # Extract the value of Cmax and cast to float 
        conc = float(cmax["Vanco conc [REF] mg/L"]) 
 
        # Find out the hour value and add to the base date time of 1/1/21 (so 
that the value can be added to TCIWorks as date/time) 
        date_time = datetime.datetime(2021, 1, 1, 0, 0, 0) + 
timedelta(hours=int(cmax["Time(hr)"])) 
 
        return { 
            "conc": conc, 
            "time": date_time.time(), 
            "date": date_time.date() 
        } 
 
    def get_dose_Cmin (patient_id, dose): 
        """ 
        Gets the Cmin concentration for a specific dose based on the maintenance 
tau 
        """ 
        maintenance_tau = int(included_subjects[included_subjects["id"] == 
patient_id]["maintenance_tau"]) 
        dose_start_time = (dose - 1) * maintenance_tau 
        dose_end_time = dose_start_time + maintenance_tau 
 
        # We know that the Cmin is going to be right on the next dose so just 
get the row that corresponds to this 
        Cmin = nonmem_df[(nonmem_df["ID"] == patient_id) & 
(nonmem_df["Time(hr)"] == dose_end_time)].iloc[[1]] 
        date_time = datetime.datetime(2021, 1, 1, 0, 0, 0) + 
timedelta(hours=int(Cmin["Time(hr)"])) 
        return { 
            "conc": float(Cmin["Vanco conc [REF] mg/L"]), 
            "time": date_time.time(), 
            "date": date_time.date() 
        } 
 
    def get_course_data(patient_id): 
        """ 
        Function to get the details of the course 
 
        Returns a list of dictionaries with the following format: 
        [ 
            {amt : amount in mg, 
            duration : infusion duration in min (based on 500mg/30 minutes) 
            date : date of dose, 
            time : time of dose 
            } 
        ] 
        """ 
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        doses = nonmem_df[(nonmem_df["ID"] == patient_id) & (nonmem_df["Dose 
(mg)"] != 0)] 
        return [ 
            { 
                "amt": dose[1]["Dose (mg)"], 
                "duration": (dose[1]["Dose (mg)"] / 500) * 30, 
                "date": (datetime.datetime(2021, 1, 1, 0, 0, 0) + 
timedelta(hours=int(dose[1]["Time(hr)"]))).date(), 
                "time": (datetime.datetime(2021, 1, 1, 0, 0, 0) + 
timedelta(hours=int(dose[1]["Time(hr)"]))).time() 
            } 
            for dose in doses.iterrows() 
        ] 
 
    def get_patient_data(patient_id): 
        """ 
        :param patient_id: ID of the patient in the database 
        :return: dictionary with the format above 
        """ 
        patient = df_subjects[(df_subjects["id"] == patient_id)].iloc[0] 
        return { 
            "first_name": "Subject", 
            "surname": patient_id, 
            "sex": patient["sex"], 
            "age": patient["age"], 
            "height": patient["height"], 
            "weight": patient["weight_tbw"], 
            "scr": patient["dose1_scr"] 
 
        } 
 
    data = {} 
    # going over the new dataframe and creating the dictionary with the unique 
IDs (skipping the header) 
    bar = ChargingBar("Processing", max=len(nonmem_df)) 
    for row in nonmem_df.iterrows(): 
        patient_id = int(row[1]["ID"]) 
        if patient_id not in data: 
            data[patient_id] = { 
                "patient_details": get_patient_data(patient_id), 
                "course_data": get_course_data(patient_id), 
                "dose1_Cmax": get_dose_Cmax(patient_id, 1), 
                "dose1_Cmin": get_dose_Cmin(patient_id, 1), 
                "dose2_Cmax": get_dose_Cmax(patient_id, 2), 
                "dose2_Cmin": get_dose_Cmin(patient_id, 2), 
                "dose3_Cmin": get_dose_Cmin(patient_id, 3), 
                "dose4_Cmin": get_dose_Cmin(patient_id, 4), 
                "dose5_Cmin": get_dose_Cmin(patient_id, 5) 
            } 
        bar.next() 
    bar.finish() 
    return data 
 
class ConcentrationError(Exception): 
    pass 
 
def enter_into_tciworks(patients, skip, create, course): 
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    """ 
    Main high-level function to enter the data from the dictionary into TCIWorks 
    """ 
    pyautogui.PAUSE = 0.25 
    pyautogui.FAILSAFE = True 
 
    def create_patient(patient): 
        pyautogui.click(x=96, y=750) 
        popup = gw.getActiveWindow() 
        popup.moveTo(0, 0) 
        pyautogui.write(f"{patient['patient_details']['surname']}") 
        pyautogui.press("tab") 
        pyautogui.write(f"{patient['patient_details']['first_name']}") 
        pyautogui.press("tab") 
        pyautogui.write(f"{patient['patient_details']['age']}") 
        pyautogui.press("tab") 
        if patient['patient_details']["sex"] == "M": 
            pyautogui.press(["down", "down"]) 
        pyautogui.press("tab") 
        pyautogui.write(f"{patient['patient_details']['height']}") 
        pyautogui.press(["tab", "tab"]) 
        
pyautogui.write("VAN"+f"{patient['patient_details']['surname']}".zfill(3)) 
        pyautogui.press("tab") 
        pyautogui.click(x=640, y=360) 
        return None 
 
    def search_for_patient(patient): 
        pyautogui.click(x=930, y=103) 
        pyautogui.hotkey('ctrl', 'a') 
        pyautogui.press('delete') 
        pyautogui.write(f"{patient['patient_details']['surname']}") 
        pyautogui.click(x=955, y=178) 
        pyautogui.click(clicks=2, x=690, y=255, interval=0.25) 
        gw.getActiveWindow().moveTo(0, 0) 
        pyautogui.click(clicks=2, x=200, y=285, interval=0.25) 
        if course: 
            pyautogui.click(x=1250, y=732) 
        while gw.getActiveWindow().title != "Patient Display": 
            time.sleep(1) 
        gw.getActiveWindow().resizeTo(1024, 740) 
        gw.getActiveWindow().moveTo(0, 0) 
 
        if "Problem Retrieving Patient List" in gw.getAllTitles(): 
            raise Exception 
 
    def add_treatment_course(patient): 
        """ 
        Next step, make the treatment course 
        :param patient: 
        :return: 
        """ 
        gw.getActiveWindow().resizeTo(1024, 740) 
        course_data = patient['course_data'] 
 
        # get the loading dose set up (as the weight and scr carry 
        pyautogui.click(x=44, y=330) 
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        pyautogui.click(x=50, y=380) 
        pyautogui.write("1/1/21") 
        pyautogui.press('tab') 
        pyautogui.write("0") 
        pyautogui.press('tab') 
        pyautogui.write(f"{int(course_data[0].get('amt'))}") 
        pyautogui.press('tab') 
        pyautogui.write(f"{int(course_data[0].get('duration'))}") 
        pyautogui.press('tab') 
        pyautogui.write(f"{patient['patient_details']['weight']}") 
        pyautogui.press(['tab', 'tab']) 
        pyautogui.write(f"{patient['patient_details']['scr']/1000}") 
 
        row = 1 
        for dose in course_data[1:]: 
            pyautogui.click(x=44, y=330) 
            pyautogui.click(x=50, y=380) 
            for i in range(row): 
                pyautogui.press('down') 
            pyautogui.write(f"{dose['date'].strftime('%d/%m/%Y')}") 
            pyautogui.press('tab') 
            pyautogui.write(f"{dose['time'].strftime('%H:%M')}") 
            pyautogui.press('tab') 
            pyautogui.write(f"{int(dose['amt'])}") 
            pyautogui.press('tab') 
            pyautogui.write(f"{int(dose['duration'])}") 
            pyautogui.press(['tab', 'tab', 'tab']) 
            pyautogui.write(f"{patient['patient_details']['scr']/1000}") 
            row += 1 
        return None 
 
    def get_report(surname, name): 
        """ 
        Gets the report for the patient it's on, assumes it's from the treatment 
screen 
        :param: name is the name to be added to the file name 
        :return: nothing 
        """ 
        pyautogui.click(x=875, y=700) 
 
        if "Concentrations Have The Same Date!" in gw.getAllTitles(): 
            print("Error!") 
            raise ConcentrationError 
        window = gw.getWindowsWithTitle("Select Number of Days")[0] 
        window.moveTo(0, 0) 
        pyautogui.click(x=100, y=80) 
        pyautogui.click(x=100, y=230) 
        pyautogui.click(x=400, y=140) 
        while gw.getActiveWindow().title == "Please wait . . .": 
            time.sleep(1) 
        gw.getActiveWindow().resizeTo(1024, 740) 
        gw.getActiveWindow().moveTo(0, 0) 
        pyautogui.click(x=17, y=40) 
        while gw.getActiveWindow().title == "Dosing Report": 
            time.sleep(1) 
        gw.getActiveWindow().moveTo(0, 0) 
        pyautogui.click(x=50, y=90, clicks=2, interval=0.25) 
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        pyautogui.click(x=200, y=255) 
        pyautogui.write(f"subject{surname}{name}") 
        pyautogui.click(x=200, y=285) 
        pyautogui.click(x=400, y=415) 
        pyautogui.click(x=385, y=330) 
        gw.getWindowsWithTitle("Dosing Report")[0].close() 
 
        return None 
 
    def add_concentrations(details, report): 
        """ 
        Adds concentrations to the 
        :param details: list of concentrations 
        :return: None 
        """ 
        row = 0 
        for conc in details: 
            pyautogui.click(x=100, y=330) 
            pyautogui.click(x=100, y=380) 
            if row != 0: 
                for i in range(row): 
                    pyautogui.press('down') 
            pyautogui.write(f"{conc['date'].strftime('%d/%m/%Y')}") 
            pyautogui.press('tab') 
            pyautogui.write(f"{conc['time'].strftime('%H:%M')}") 
            pyautogui.press('tab') 
            pyautogui.write(f"{conc['conc']}") 
            row += 1 
        get_report(surname=report['surname'], name=report['name']) 
        return None 
 
    def clear_concentrations(clicks): 
        """ 
        Clears the concentrations date 
        :return:None 
        """ 
        while gw.getActiveWindow().title != "Patient Display": 
            time.sleep(1) 
        pyautogui.click(x=710, y=330, clicks=clicks, interval=0.5) 
        if gw.getActiveWindow().title == "Delete Failed": 
            gw.getActiveWindow().close() 
            gw.getWindowsWithTitle("Patient Display")[0].close() 
        return None 
 
    def close_dosing_screen(): 
        gw.getWindowsWithTitle("Patient Display")[0].close() 
        return None 
 
    def get_data(patient): 
        # Get the report for no data 
        try: 
            get_report(patient['patient_details']['surname'], "nothing") 
 
            # Go into the dosing screen 
            pyautogui.click(x=225, y=668) 
 
            # Scenario 1: dose 1 Cmax & Cmin 
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            add_concentrations([patient['dose1_Cmax'], patient['dose1_Cmin']], 
                               {'surname': 
patient['patient_details']['surname'], 'name': 'd1pt'} 
                               ) 
            clear_concentrations(2) 
 
            # Scenario 2: dose 2 Cmax & Cmin 
            add_concentrations([patient['dose2_Cmax'], 
                                patient['dose2_Cmin']], 
                               {'surname': 
patient['patient_details']['surname'], 'name': 'd2pt'} 
                               ) 
            clear_concentrations(2) 
 
            # Scenario 3: dose 1 Cmin only 
            add_concentrations([patient['dose1_Cmin'], ], 
                               {'surname': 
patient['patient_details']['surname'], 'name': 'd1t'}) 
            clear_concentrations(1) 
 
            # Scenario 4: dose 2 Cmin only 
            add_concentrations([patient['dose2_Cmin'], ], 
                               {'surname': 
patient['patient_details']['surname'], 'name': 'd2t'}) 
            clear_concentrations(1) 
 
            # Scenario 5: dose 3 Cmin only 
            add_concentrations([patient['dose3_Cmin'], ], 
                               {'surname': 
patient['patient_details']['surname'], 'name': 'd3t'}) 
            clear_concentrations(1) 
 
            # Scenario 6: dose 4 Cmin only 
            add_concentrations([patient['dose4_Cmin'], ], 
                               {'surname': 
patient['patient_details']['surname'], 'name': 'd4t'}) 
            clear_concentrations(1) 
 
            # Scenario 7: dose 5 Cmin only 
            add_concentrations([patient['dose5_Cmin'], ], 
                               {'surname': 
patient['patient_details']['surname'], 'name': 'd5t'}) 
            clear_concentrations(1) 
 
            # Scenario 8: dose 2 and 3 Cmin only 
            add_concentrations([patient['dose2_Cmin'], 
                                patient['dose3_Cmin']], 
                               {'surname': 
patient['patient_details']['surname'], 'name': 'd23t'}) 
            clear_concentrations(2) 
        except ConcentrationError: 
            gw.getWindowsWithTitle("Concentrations Have The Same 
Date!")[0].close() 
            pyautogui.click(x=175, y=670) 
            pyautogui.click(x=165, y=380) 
            clear_concentrations(4) 




    def open_TCIWorks(): 
        print("Opening TCIWorks") 
        pyautogui.hotkey('winleft', 'd') 
        pyautogui.press(["t", "enter"]) 
        while "Select Data Source" not in gw.getAllTitles(): 
            time.sleep(1) 
        gw.getWindowsWithTitle("Select Data Source")[0].moveTo(0, 0) 
        pyautogui.click(x=240, y=270) 
        pyautogui.write("atticus") 
        pyautogui.click(x=320, y=310) 
        while gw.getActiveWindow().title != "TCIWorks 1.0-RC1": 
            time.sleep(1) 
        return None 
 
    def close_TCIWorks(): 
        windows = gw.getAllTitles() 
        if "Patient Display" in windows: 
            gw.getWindowsWithTitle("Patient Display")[0].close() 
        if "TCIWorks 1.0-RC1" in windows: 
            gw.getWindowsWithTitle("TCIWorks 1.0-RC1")[0].close() 
            while gw.getActiveWindow().title != "Confirm Close": 
                time.sleep(1) 
            pyautogui.hotkey('alt', 'y') 
        return None 
 
    starttime = datetime.datetime.now() 
    print(starttime) 
    for patient in patients.keys(): 
 
        if patient <= skip: 
            pass 
            print(f"Patient {patient} already completed") 
        else: 
            if 'TCIWorks 1.0-RC1' not in gw.getAllTitles(): 
                open_TCIWorks() 
            patient_start = datetime.datetime.now() 
            main_window = gw.getWindowsWithTitle('TCIWorks 1.0-RC1')[0] 
            main_window.resizeTo(1024, 740) 
            main_window.moveTo(0, 0) 
            main_window.activate() 
            # create the patient 
            print(f"Working on patient {patient}") 
            if create: 
                create_patient(patients[patient]) 
            # Add the treatment course 
            try: 
                search_for_patient(patients[patient]) 
            except Exception: 
                close_TCIWorks() 
                open_TCIWorks() 
                search_for_patient(patients[patient]) 
            if course: 
                add_treatment_course(patients[patient]) 
            try: 
                get_data(patients[patient]) 
            except IndexError: 
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                print("Error selecting window") 
 
                break 
            close_dosing_screen() 
            close_TCIWorks() 
            print(f"Entered {patient} in {datetime.datetime.now() - 
patient_start}") 
        print(f"Total time {datetime.datetime.now() - starttime}") 
 
 
if __name__ == "__main__": 
    main(skip=0, create=False, course=False) 
 
 
Figure 5.2: TCIWorks dosing screen with course entered for subject 1. 
Appendix 5.2.4: Calculation of AUCssTest: 0-24h 
For each individual-limited sampling strategy permutation, the following script calculated the 
AUCssTest: 0-24h from the relevant course report file. This value was obtained by summing all rows where the 
date was recorded as 10/1/21 (as this was day 10). For reassurance that the data was entered into TCIWorks 
was correct, several items on the Course Report were checked against the known values: ID (and that the 
original script selected the correct data), age, weight and serum creatinine. Figure 5.3 demonstrates the 
Course Report from subject 1 with the limited sampling strategy using the prior model only, the sum of the 
yellow highlighted values represents the AUCssTest: 0-24h. 
import pandas as pd 
 
 
def validate_sheet(sheet, patient_id): 
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    included_subjects = pd.read_csv(r"data\included_subjects.csv") 
    patient_data = included_subjects.loc[included_subjects["id"] == 
patient_id] 
 
    # the ID is on row 2 
    sheet_id = int(sheet.iloc[[2]].dropna(axis='columns').iloc[-
1].tail(1).item()) 
    assert sheet_id == patient_id, f"Wrong id on sheet {sheet}: {sheet_id}, 
{patient_id}" 
 
    # Age is on row 3, but the second to last column 
    sheet_age = sheet.iloc[[3]].dropna(axis='columns') 
    sheet_age = int(sheet_age[sheet_age.columns[-2]]) 
    assert sheet_age == patient_data["age"].item(), f"Wrong age on sheet 
{patient_id}: sheet age {sheet_age}, patient age {patient_data['age']}" 
 
    # Weight and scr are on the same row  
    filters = sheet["Unnamed: 0"].str.contains("^10/01", na=False) 
    res = sheet[filters].dropna(axis='columns').iloc[[0]] 
 
    # first weight 
    sheet_weight = int(float(res[res.columns[3]].item())) 
    patient_weight = patient_data["weight_tbw"].item() 
    assert sheet_weight == patient_weight, f"Wrong weight on sheet 
{patient_id}: sheet weight {sheet_weight}, patient weight {patient_weight}" 
 
    # Next SCr 
    sheet_scr = int(float(res[res.columns[4]].item()) * 1000) 
    patient_scr = patient_data["dose1_scr"].item() 
    assert sheet_scr == patient_scr, f"Wrong SCr on sheet {patient_id}: sheet 
Scr {sheet_scr}, patient SCr {patient_scr}" 
 
def get_auc10_test(patient_id, scenario): 
    """ 
    Gets the reference data for each scenario.  
 
    Returns a single int, the AUC24 for day 10 
    """ 
    data = 
pd.DataFrame(pd.read_csv(rf"automation\data\subject{patient_id}{scenario}.csv
")) 
    print(patient_id, scenario) 
    validate_sheet(data, patient_id) 
    filters = data["Unnamed: 0"].str.contains("^10/01", na=False) 
    # Filtering to the correct rows and dropping the na values 
    res = data[filters].dropna(axis='columns') 
    # Grabbing the last column which is the AUC value 
    res = res[res.columns[-1]] 
    # Return the sum 
    return pd.to_numeric(res).sum() 
 
 
results = pd.read_csv(r"data\reference_auc_data_template.csv") 
# for 3 sets of data 
for index, row in results.iterrows(): 
    results.loc[index, "nothing"] = get_auc10_test(int(row["id"]), "nothing") 
    results.loc[index, "AUCp_t1"] = get_auc10_test(int(row["id"]), "d1pt") 
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    results.loc[index, "AUCp_t2"] = get_auc10_test(int(row["id"]), "d2pt") 
    results.loc[index, "AUCt1"] = get_auc10_test(int(row["id"]), "d1t") 
    results.loc[index, "AUCt2"] = get_auc10_test(int(row["id"]), "d2t") 
    results.loc[index, "AUCt3"] = get_auc10_test(int(row["id"]), "d3t") 
    results.loc[index, "AUCt4"] = get_auc10_test(int(row["id"]), "d4t") 
    results.loc[index, "AUCt5"] = get_auc10_test(int(row["id"]), "d5t") 










Figure 5.3: Screenshot from TCIWorks report with the day 10 values for AUC highlighted. Highlighted values are summed to give 
value of AUCssTest: 0-24h, in this example subject using the prior model only. 
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Appendix 5.3: Analysis of data 


















Appendix 5.3.2: Data import and manipulation 
nonmem_data_MAP = read_rds("./data/nonmem_data_filtered.rds") 
 
excluded_subjects = read_rds("./data/excluded_subjects.rds") %>% 
  mutate( 
    ethnicity = as.factor(ethnicity), 
    dialysis = factor(dialysis, levels=c("TRUE", "FALSE"), labels=c("Yes", "No")), 
    no_height = factor(no_height, levels=c("TRUE", "FALSE"), labels=c("Yes", "No")), 
    no_weight = factor(no_weight, levels=c("TRUE", "FALSE"), labels=c("Yes", "No")), 
    no_scr = factor(no_scr, levels=c("TRUE", "FALSE"), labels=c("Yes", "No")), 
    age_wrong = factor(age_wrong, levels=c("TRUE", "FALSE"), labels=c("Yes", "No")), 
    renal_function = factor(renal_function, levels=c("TRUE", "FALSE"), labels=c("Yes", "No")), 
    no_maintenance_dose = factor(no_maintenance_dose, levels=c("TRUE", "FALSE"), labels=c("Yes
", "No")) 
  ) 
 
auc_data = read.csv("./automation/auc_data_automation.csv") %>%  
  mutate( 
  is_obese = factor(is_obese, levels=c("TRUE", "FALSE"), labels=c("Obese", "Non-obese")), 
  sex = factor(sex, levels=c("M", "F"), labels=c("Male", "Female")), 
  id = as.factor(id), 
  ethnicity = as.factor(ethnicity), 
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  ethnicity = relevel(ethnicity, "NZ European/Pakeha") 
) %>%  
  var_labels( 
    sex = "Sex", 
    ethnicity = "Ethnicity", 
    height = "Height (cm)", 
    age = "Age (years)", 
    weight_tbw = "Total body weight (kg)", 
    crcl_tbw = "Creatinine clearance (mL/min)", 
    bmi = "Body mass index (kg/m^2)", 
    dose1_amt = "Dose 1 amount (mg)", 
    dose2_amt = "Dose 2 amount (mg)", 
    dose3_amt = "Dose 3 amount (mg)", 
    dose4_amt = "Dose 4 amount (mg)", 
    dose5_amt = "Dose 5 amount (mg)", 
    dose1_scr = "Baseline serum creatinine (umol/L)", 
    dose2_scr = "Serum creatinine at dose 2 (umol/L)", 
    dose3_scr = "Serum creatinine at dose 3 (umol/L)", 
    dose4_scr = "Serum creatinine at dose 4 (umol/L)", 
    dose5_scr = "Serum creatinine at dose 5 (umol/L)", 
    dose1_mg_kg = "Dose 1 mg/kg", 
    dose2_mg_kg = "Dose 2 mg/kg", 
    dose3_mg_kg = "Dose 3 mg/kg", 
    dose4_mg_kg = "Dose 4 mg/kg", 
    dose5_mg_kg = "Dose 5 mg/kg", 
    maintenance_tau = "Frequency of maintenance dose (hr)", 
    dialysis = "Patient on dialysis", 
    is_obese = "Obesity status" 
  ) 
Appendix 5.3.3: Summary tables and plots 
auc_data %>% 
  var_labels(sex = "Sex") %>% 
  copy_labels(auc_data) %>% 
  cross_tab(is_obese ~ age + sex + height + weight_tbw + bmi + crcl_tbw  + dose1_scr + ethnici
ty + auc10, method=2) %>% 
  as_hux %>% 
  theme_article 
excluded_subjects %>% 
  select(renal_function, age_wrong, no_height, no_weight, no_maintenance_dose, no_scr, dialysi
s) %>% 
  var_labels( 
    no_maintenance_dose = "Missing maintenance dose", 
    renal_function = "Renal function < 30mL/min", 
    dialysis = "On dialysis" 
  ) %>% 
  moonBook::mytable(.) %>% 
  as_hux %>% 
  theme_article() 
auc_data %>% 
  copy_labels(auc_data) %>% 
  cross_tab(is_obese ~ dose1_amt + dose2_amt + dose3_amt + dose4_amt + dose5_amt + dose1_mg_kg 
+ dose2_mg_kg + dose3_mg_kg + dose4_mg_kg + dose5_mg_kg + maintenance_tau, label="", method=2) 
%>% 
  as_hux(add_colnames = TRUE) %>% 
  insert_row(c(" ", " ", "Obesity status"), fill = " ") %>% 
  theme_article 
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auc_data %>% frq(maintenance_tau) 
nonmem_data_MAP %>% filter(`Dose (mg)` != 0) %>% estat(~`Dose (mg)`) 
nonmem_data_MAP %>% filter(`Dose (mg)` != 0) %>% mutate(mg_kg = `Dose (mg)` / WTKG) %>% estat(
~ mg_kg) 
auc_data %>% select(dose1_amt, dose2_amt, dose3_amt, dose4_amt, dose5_amt) %>% frq() 
b_a_data = auc_data %>%  
  melt(., id=c("id", "is_obese", "auc10"), measure.vars=c("nothing", "AUCt1", "AUCt2", "AUCt3"
, "AUCt4", "AUCt5", "AUCt2_3", "AUCp_t1", "AUCp_t2")) %>% 
         mutate( 
           difference = value - auc10, 
           mean = (value+auc10)/2 
         ) 
ba_graph_data = b_a_data %>% 
  mutate() %>%  
  df_stats(~difference, mean = mean, sd = sd) %>% mutate(lowerci = -1.96*sd + mean, upperci=1.
96*sd + mean) 
 
b_a = b_a_data %>% 
  gf_point(difference ~ mean, size=0.6, ylab=ylab, xlab=xlab, title="b)") %>% 
  gf_hline(yintercept=~mean, data=ba_graph_data, size=0.2, color='blue') %>% 
  gf_hline(yintercept=~lowerci, data=ba_graph_data, size=0.2, linetype="dashed", color='blue') 
%>% 
  gf_hline(yintercept=~upperci, data=ba_graph_data, size=0.2, linetype="dashed", color='blue') 
%>% 
  gf_lm(color='indianred') 
 
lms = auc_data %>% 
  melt(., id=c("id", "is_obese", "auc10"), measure.vars=c("nothing", "AUCt1", "AUCt2", "AUCt3"
, "AUCt4", "AUCt5", "AUCt2_3", "AUCp_t1", "AUCp_t2")) %>% 
  gf_point( 
   value ~ auc10, xlab=latex2exp::TeX("$AUCss_{Ref:0-24h}"), ylab=latex2exp::TeX("$AUCss_{Test
:0-24h}"),  
    title = "a)", size=0.8 
    ) %>% 
  gf_abline(slope=1, intercept=0, color='indianred') 
library(ggpubr) 
ggarrange(lms, b_a) 
auc_data %>% gf_density(~ age|sex, fill = ~is_obese, alpha=0.5) %>% axis_labs() %>% gf_labs(fi
ll=get_label(auc_data$is_obese)) 
auc_data %>% gf_density(~ height|sex, fill = ~is_obese, alpha=0.5) %>% axis_labs() %>% gf_labs
(fill=get_label(auc_data$is_obese)) 
auc_data %>% gf_density(~ weight_tbw|sex, fill = ~is_obese, alpha=0.5) %>% axis_labs() %>% gf_
labs(fill=get_label(auc_data$is_obese)) 
auc_data %>% gf_density(~ crcl_tbw|sex, fill = ~is_obese, alpha=0.5) %>% axis_labs() %>% gf_la
bs(fill=get_label(auc_data$is_obese)) 
Appendix 5.3.4: Metrics of accuracy, bias and imprecision 
table_data = auc_data %>%  
  melt(., id=c("id", "is_obese", "auc10"), measure.vars=c("nothing", "AUCt1", "AUCt2", "AUCt3"




  mutate( 
    pe = auctest - auc10, 
    ratio = auctest/auc10, 
    rel_bias = 100 * ((auctest-auc10)/auc10), 
    p20 = rel_bias >= -20 & rel_bias <= 20, 
     test = as.factor(ifelse(test == "nothing", "Prior model only",  
                  ifelse(test == "AUCt1", "Dose 1 Cmin", 
                         ifelse(test == "AUCt2", "Dose 2 Cmin", 
                                ifelse(test=="AUCt3", "Dose 3 Cmin",  
                                       ifelse(test=="AUCt4", "Dose 4 Cmin", 
                                              ifelse(test=="AUCt5", "Dose 5 Cmin", 
                                                     ifelse(test=="AUCp_t1", "Dose 1 Cmax and 
Cmin",  
                                                            ifelse(test=="AUCp_t2", "Dose 2 Cm
ax and Cmin", 
                                                                   ifelse(test=="AUCt2_3", "Do
ses 2 and 3 Cmins", "") 
                                                                   ) 
                                                            ) 
                                                     ) 
                                              ) 
                                       ) 
                                ) 
                         ) 
                  )), 
    test = relevel(test, "Dose 2 Cmax and Cmin"), 
    test = relevel(test, "Dose 1 Cmax and Cmin"), 
    test = relevel(test, "Doses 2 and 3 Cmins"), 
    test = relevel(test, "Dose 5 Cmin"), 
    test = relevel(test, "Dose 4 Cmin"), 
    test = relevel(test, "Dose 3 Cmin"), 
    test = relevel(test, "Dose 2 Cmin"), 
    test = relevel(test, "Dose 1 Cmin"), 
    test = relevel(test, "Prior model only") 
  ) 
 
table_data %>% 
  group_by(test) %>% 
  dplyr::summarise( 
    mpe = glue( 
        "{round(mean(pe), 2)} ({round(confint(t.test(~pe))['lower'], 2)}, {round(confint(t.tes
t(~pe))['upper'], 2)})"), 
    mse = mean(pe^2), 
    rmse = mse^0.5, 
    ratio = glue( 
      "{round(Gmean(ratio), 3)} ({round(Gmean(ratio, conf.level=0.90)['lwr.ci'], 3)}, {round(G
mean(ratio, conf.level=0.90)['upr.ci'], 3)})" 
      ), 
    p20s = glue( 
        "{round(confint(binom.test(~p20, conf.level=0.95))['probability of success']* 100, 0)y 
({round(confint(binom.test(~p20, conf.level=0.95))['lower']* 100, 0)y, {round(confint(binom.te
st(~p20, conf.level=0.95))['upper']* 100, 0)})" 
        ) 
  ) %>% select(-mse) %>% 
  as_hux(add_colnames=F) %>% 
  insert_row(c("Test", "Mean Prediction Error (mg.h/L)", "Root Mean Square Error", "AUCtest:AU
CRef", "P20")) %>% 
  theme_article() 
table_data %>% box_plot(pe ~ test, ylab="Prediction Error (mg.h/L)", xlab="Test scenario")%>% 




  box_plot(rel_bias ~ test, xlab = "Limited sampling strategy", ylab ="Relative prediction err
or (%)") %>% 
  gf_theme(axis.text.x=element_text(angle=90, hjust=1)) 
table_data %>% 
  box_plot(rel_bias ~ test|is_obese, xlab = "Limited sampling strategy", ylab ="Relative predi
ction error (%)") %>% 
  gf_theme(axis.text.x=element_text(angle=90, hjust=1)) 
ylab = latex2exp::TeX("$AUCss_{Test:0-24h}$ - $AUCss_{Ref:0-24h} / Mean($AUCss_{Test:0-24h}$ a
nd $AUCss_{Ref:0-24h})") 
xlab = latex2exp::TeX("Mean ($AUCss_{Test:0-24h}$ and $AUCss_{Ref:0-24h})") 
relative_plot_summary = table_data %>%  
  df_stats(difference/mean ~ test, mean = mean, sd = sd) %>%  
  mutate(lowerci = -1.96*sd + mean, upperci=1.96*sd + mean) 
relative_plot_summary_obese = table_data %>% filter(is_obese == "Obese") %>%  
  df_stats(difference/mean ~ test, mean = mean, sd = sd) %>%  
  mutate(lowerci = -1.96*sd + mean, upperci=1.96*sd + mean) 
relative_plot_summary_non_obese = table_data %>% filter(is_obese == "Non-obese") %>%  
  df_stats(difference/mean ~ test, mean = mean, sd = sd) %>%  
  mutate(lowerci = -1.96*sd + mean, upperci=1.96*sd + mean) 
table_data %>%  
  gf_point((difference / mean) ~ mean | test, size = 0.6, xlab=xlab, ylab=ylab) %>% 
  gf_hline(yintercept=~mean, data=relative_plot_summary, size=0.2, color='blue') %>% 
  gf_hline(yintercept=~lowerci, data=relative_plot_summary, size=0.2, linetype="dashed", color
='blue') %>% 
  gf_hline(yintercept=~upperci, data=relative_plot_summary, size=0.2, linetype="dashed", color
='blue') %>% 
  gf_lm(color='indianred') 
table_data %>% filter(is_obese == "Obese") %>% 
  gf_point((difference / mean) ~ mean| test, size = 0.6, xlab=xlab, ylab=ylab) %>% 
  gf_hline(yintercept=~mean, data=relative_plot_summary_obese, size=0.2, color='blue') %>% 
  gf_hline(yintercept=~lowerci, data=relative_plot_summary_obese, size=0.2, linetype="dashed", 
color='blue') %>% 
  gf_hline(yintercept=~upperci, data=relative_plot_summary_obese, size=0.2, linetype="dashed", 
color='blue') %>% 
  gf_lm(color='indianred') 
table_data %>% filter(is_obese == "Non-obese") %>% 
  gf_point((difference / mean) ~ mean | test, size = 0.6, xlab=xlab, ylab=ylab) %>% 
  gf_hline(yintercept=~mean, data=relative_plot_summary_non_obese, size=0.2, color='blue') %>% 
  gf_hline(yintercept=~lowerci, data=relative_plot_summary_non_obese, size=0.2, linetype="dash
ed", color='blue') %>% 
  gf_hline(yintercept=~upperci, data=relative_plot_summary_non_obese, size=0.2, linetype="dash
ed", color='blue') %>% 
  gf_lm(color='indianred') 
Appendix 5.3.5: Multilinear regression model 
mlrData = auc_data %>% 
  melt(., id.vars=c("id", "sex", "age", "height", "weight_tbw", "bmi", "is_obese", "dose1_scr"
, "maintenance_tau", "ethnicity", "auc10"), measure.vars=c"AUCt2_3”), variable.name="test", va
lue.name="AUCTest") %>%  
  mutate ( 
    maintenance_tau = as.factor(maintenance_tau), 
    abs_bias = AUCTest - auc10, 
    maintenance_tau = relevel(maintenance_tau, "12") 
    ) %>% 
  select(-id, -AUCTest, -auc10) 
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model_1 = lm( 
  abs_bias ~ sex + age + bmi + dose1_scr + ethnicity + maintenance_tau, data=mlrData) 
model_1_aic = step(model_1, trace=FALSE) 
model_1_aic %>% 
  center_mod() %>% 
  glm_coef( 
    labels = c( 
      model_labels(model_1) 
  ) %>% 
  as_hux %>% set_align(everywhere, 2:3, "right") %>% 
  theme_article 
# Model diagnostics 
plots = model_1_aic %>% 
  center_mod() %>% 
  sjPlot::plot_model("diag", dot.size = 1) 
plots[[1]] = plots[[1]] %>% 
  gf_theme(axis.text.x=element_text(angle=90, hjust=1)) 
ggarrange( plots[[2]], plots[[3]], plots[[4]]) 
plots[[1]] 
Appendix 5.3.6: Stratification by obesity 
ylab = latex2exp::TeX("$AUCss_{Test:0-24h} - AUCss_{Ref:0-24h}$") 
xlab = latex2exp::TeX("Average of $AUCss_{Test:0-24h}$ and $AUCss_{Ref:0-24h}$") 
obese = b_a_data %>% filter(is_obese == "Obese") 
obese_data = obese %>% 
  mutate() %>%  
  df_stats(~difference, mean = mean, sd = sd) %>% mutate(lowerci = -1.96*sd + mean, upperci=1.
96*sd + mean) 
 
b_a_obese = obese %>%  
  gf_point(difference ~ mean, size=0.6, ylab=ylab, xlab=xlab, title = "c)") %>% 
  gf_hline(yintercept=~mean, data=obese_data, size=0.2, color='blue') %>% 
  gf_hline(yintercept=~lowerci, data=obese_data, size=0.2, linetype="dashed", color='blue') %>
% 
  gf_hline(yintercept=~upperci, data=obese_data, size=0.2, linetype="dashed", color='blue') %>
% 
  gf_lm(color='indianred')%>% gf_lims(x=c(0, 1750), y=c(-600, 600)) 
 
obese_xy = obese %>% gf_point(value ~ auc10, size=0.8, xlab=latex2exp::TeX("$AUCss_{Ref:0-24h}
"),ylab = latex2exp::TeX("$AUCss_{Test:0-24h}"), title="a)") %>%  
  gf_abline(intercept=0, slope=1, color='indianred') %>% gf_lims(y=c(0, 1600), x=c(0, 1600)) 
non_obese = b_a_data %>% filter(is_obese == "Non-obese") 
non_obese_data = non_obese %>% 
  mutate() %>%  
  df_stats(~difference, mean = mean, sd = sd) %>% mutate(lowerci = -1.96*sd + mean, upperci=1.
96*sd + mean) 
 
b_a_non_obese = non_obese %>%  
  gf_point(difference ~ mean, size=0.6, ylab=ylab, xlab=xlab, title="d)") %>% 
  gf_hline(yintercept=~mean, data=non_obese_data, size=0.2, color='blue') %>% 
  gf_hline(yintercept=~lowerci, data=non_obese_data, size=0.2, linetype="dashed", color='blue'
) %>% 




  gf_lm(color='indianred')%>% gf_lims(x=c(0, 1750), y=c(-600, 600)) 
 
non_obese_xy = non_obese %>% gf_point(value ~ auc10, size=0.8, xlab=latex2exp::TeX("$AUCss_{Re
f:0-24h}"),ylab = latex2exp::TeX("$AUCss_{Test:0-24h}"), title="b)") %>%  
  gf_abline(intercept=0, slope=1, color='indianred') %>% gf_lims(x=c(0, 1600), y=c(0, 1600)) 
tab_obese = table_data %>% filter(is_obese == "Obese")  %>% 
  group_by(test) %>% 
  dplyr::summarise( 
      mpe_obese = glue( 
         "{round(mean(pe), 2)} ({round(confint(t.test(~pe))['lower'], 2)}, {round(confint(t.te
st(~pe))['upper'], 2)})" 
      ), 
      mse = mean(pe^2), 
      rmse_obese = mse^0.5, 
      obese_ratios = 
        glue( 
        "{round(Gmean(ratio), 3)} ({round(Gmean(ratio, conf.level=0.90)['lwr.ci'], 3)}, {round
(Gmean(ratio, conf.level=0.90)['upr.ci'], 3)})" 
        ), 
      obese_p20s = glue( 
        "{round(confint(binom.test(~p20, conf.level=0.95))['probability of success']* 100, 0)} 
({round(confint(binom.test(~p20, conf.level=0.95))['lower']* 100, 0)}, {round(confint(binom.te
st(~p20, conf.level=0.95))['upper']* 100, 0)})" 
        ) 
  ) %>% select(-mse) 
 
tab_non_obese = table_data %>% filter(is_obese == "Non-obese") %>% 
  group_by(test) %>% 
  dplyr::summarise( 
      mpe_non_obese = glue( 
         "{round(mean(pe), 2)} ({round(confint(t.test(~pe))['lower'], 2)}, {round(confint(t.te
st(~pe))['upper'], 2)})" 
      ), 
      mse = mean(pe^2), 
      rmse_non_obese = mse^0.5, 
      non_obese_ratios = 
        glue( 
        "{round(Gmean(ratio), 3)} ({round(Gmean(ratio, conf.level=0.90)['lwr.ci'], 3)}, {round
(Gmean(ratio, conf.level=0.90)['upr.ci'], 3)})" 
        ), 
      non_obese_p20s = glue( 
        "{round(confint(binom.test(~p20, conf.level=0.95))['probability of success']* 100, 0)} 
({round(confint(binom.test(~p20, conf.level=0.95))['lower']* 100, 0)}, {round(confint(binom.te
st(~p20, conf.level=0.95))['upper']* 100, 0)})" 
        ) 
  ) %>% select(-mse) 
 
 
cbind(tab_obese, tab_non_obese[2:5]) %>% relocate("non_obese_ratios", .after=obese_ratios) %>% 
relocate(mpe_non_obese, .after="mpe_obese")  %>% relocate("rmse_non_obese", .after=rmse_obese) 
%>% 
  as_hux(add_colnames=F) %>% 
  insert_row(c("Test", "Obese", "Non-obese", "Obese", "Non-obese", "Obese", "Non-obese", "Obes
e", "Non-obese")) %>% 
  insert_row(c(" ", "Mean absolute bias"," ","RMSE"," " , "AUCssTest:0-24h:AUCssRef:0-24h", " 
", "P20", " ")) %>% 
  theme_article() 
table_data %>%  
  mutate(is_obese = relevel(is_obese, "Obese")) %>% 
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  box_plot(pe ~ test | is_obese, xlab = "Test scenario", ylab ="Prediction error (mg.h/L)") %>
% 
  gf_theme(axis.text.x=element_text(angle=90, hjust=1)) 
 
# Significance tests on non-obese group 
result_non_obese = result %>% filter(is_obese == "Non-obese") %>% mutate(p20 = rel_bias >= -20 
& rel_bias <= 20) 
cochran.qtest(p20 ~ test | id, data=result_non_obese) 
result_non_obese %>% pairwise_mcnemar_test(p20 ~ test | id, type="mcnemar", p.adjust.method = 
"bonferroni") 
 
table_data %<>%  
  mutate( 
    difference = auctest - auc10, 
    mean = (auctest + auc10)/2 
    ) 
stratified_plot_data = table_data %>% df_stats(difference ~ test, mean = mean, sd = sd) %>% mu
tate(lowerci = -1.96*sd + mean, upperci=1.96*sd + mean) 
ylab = latex2exp::TeX("$AUCss_{Test:0-24h} - AUCss_{Ref:0-24h}") 
xlab = latex2exp::TeX("Average of $AUCss_{Test:0-24h}$ and $AUCss_{Ref:0-24h}$") 
table_data %>% 
  gf_point(difference ~ mean | test, size=0.6, xlab=xlab, ylab=ylab) %>% 
  gf_hline(yintercept=~mean, data=stratified_plot_data, size=0.2, color='blue') %>% 
  gf_hline(yintercept=~lowerci, data=stratified_plot_data, size=0.2, linetype="dashed", color=
'blue') %>% 
  gf_hline(yintercept=~upperci, data=stratified_plot_data, size=0.2, linetype="dashed", color=
'blue') %>% 
  gf_lm(color='indianred') 
table_data %>% 
  gf_point( 
    auctest ~ auc10|test, xlab=latex2exp::TeX("$AUCss_{Ref:0-24h}"), ylab=latex2exp::TeX("$AUC
ss_{Test:0-24h}"),  
    title =, size=0.8 
    ) %>% 
  gf_abline(slope=1, intercept=0, color='indianred') 
table_data %>% filter(is_obese == "Non-obese") %>% 
  gf_point( 
    auc10 ~ auctest |test, xlab=latex2exp::TeX("$AUCss_{Ref:0-24h}"), ylab=latex2exp::TeX("$AU
Css_{Test:0-24h}"),  
    title =, size=0.8 
    ) %>% 
  gf_abline(slope=1, intercept=0, color='indianred') 
table_data %>% filter(is_obese == "Obese") %>% 
  gf_point( 
    auctest ~ auc10|test, xlab=latex2exp::TeX("$AUCss_{Ref:0-24h}"), ylab=latex2exp::TeX("$AUC
ss_{Test:0-24h}"),  
    title =, size=0.8 
    ) %>% 
  gf_abline(slope=1, intercept=0, color='indianred') 
ylab = latex2exp::TeX("$AUCss_{Test:0-24h} - AUCss_{Ref:0-24h}$") 
xlab = latex2exp::TeX("Average of $AUCss_{Test:0-24h}$ and $AUCss_{Ref:0-24h}$") 
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stratified_plot_data_obese = table_data %>% filter(is_obese == "Obese") %>% df_stats(differenc
e ~ test, mean = mean, sd = sd) %>% mutate(lowerci = -1.96*sd + mean, upperci=1.96*sd + mean) 
 
stratified_plot_data_non_obese = table_data %>% filter(is_obese == "Non-obese") %>% df_stats(d
ifference ~ test, mean = mean, sd = sd) %>% mutate(lowerci = -1.96*sd + mean, upperci=1.96*sd 
+ mean) 
table_data %>% filter(is_obese == "Obese") %>% 
  gf_point(difference ~ mean | test, size=0.6, xlab=xlab, ylab=ylab) %>% 
  gf_hline(yintercept=~mean, data=stratified_plot_data, size=0.2, color='blue') %>% 
  gf_hline(yintercept=~lowerci, data=stratified_plot_data, size=0.2, linetype="dashed", color=
'blue') %>% 
  gf_hline(yintercept=~upperci, data=stratified_plot_data, size=0.2, linetype="dashed", color=
'blue') %>% 
  gf_lm(color='indianred') 
table_data %>% filter(is_obese == "Non-obese") %>% 
  gf_point(difference ~ mean | test, size=0.6, xlab=xlab, ylab=ylab) %>% 
  gf_hline(yintercept=~mean, data=stratified_plot_data, size=0.2, color='blue') %>% 
  gf_hline(yintercept=~lowerci, data=stratified_plot_data, size=0.2, linetype="dashed", color=
'blue') %>% 
  gf_hline(yintercept=~upperci, data=stratified_plot_data, size=0.2, linetype="dashed", color=
'blue') %>% 
  gf_lm(color='indianred')  
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Appendix 5.4: Distribution plots of continuous variables of included subjects 
 
Figure 5.4: Density plot depicting the distribution of the included subjects age (years) by sex and obesity status. 
 




Figure 5.6: Distribution plot depicting the distribution of the included subjects total body weight (kg) stratified by sex and obesity 
status. 
 
Figure 5.7: Distribution plot depicting the distribution of the included subject’s creatinine clearance (mL/min) stratified by sex 




Appendix 5.5: Pairwise P20 comparisons for non-obese individuals 
Limited sampling strategy 1 Limited sampling strategy 2 Adjusted p-value 
Prior model only Dose 1 Cmin 1.00 
Prior model only Dose 2 Cmin 0.07 
Prior model only Dose 3 Cmin <0.01 
Prior model only Dose 4 Cmin <0.01 
Prior model only Dose 5 Cmin <0.001 
Prior model only Doses 2 and 3 Cmins <0.01 
Prior model only Dose 1 Cmax and Cmin 1.00 
Prior model only Dose 2 Cmax and Cmin 0.34 
Dose 1 Cmin Dose 2 Cmin 1.00 
Dose 1 Cmin Dose 3 Cmin 0.34 
Dose 1 Cmin Dose 4 Cmin 0.20 
Dose 1 Cmin Dose 5 Cmin <0.05 
Dose 1 Cmin Doses 2 and 3 Cmins 0.57 
Dose 1 Cmin Dose 1 Cmax and Cmin 1.00 
Dose 1 Cmin Dose 2 Cmax and Cmin 1.00 
Dose 2 Cmin Dose 3 Cmin 1.00 
Dose 2 Cmin Dose 4 Cmin 1.00 
Dose 2 Cmin Dose 5 Cmin 0.16 
Dose 2 Cmin Doses 2 and 3 Cmins 1.00 
Dose 2 Cmin Dose 1 Cmax and Cmin 1.00 
Dose 2 Cmin Dose 2 Cmax and Cmin 1.00 
Dose 3 Cmin Dose 4 Cmin 1.00 
Dose 3 Cmin Dose 5 Cmin 1.00 
Dose 3 Cmin Doses 2 and 3 Cmins 1.00 
Dose 3 Cmin Dose 1 Cmax and Cmin 0.20 
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Dose 3 Cmin Dose 2 Cmax and Cmin 1.00 
Dose 4 Cmin Dose 5 Cmin 1.00 
Dose 4 Cmin Doses 2 and 3 Cmins 1.00 
Dose 4 Cmin Dose 1 Cmax and Cmin 0.12 
Dose 4 Cmin Dose 2 Cmax and Cmin 1.00 
Dose 5 Cmin Doses 2 and 3 Cmins 1.00 
Dose 5 Cmin Dose 1 Cmax and Cmin <0.05 
Dose 5 Cmin Dose 2 Cmax and Cmin 0.20 
Doses 2 and 3 Cmins Dose 1 Cmax and Cmin 0.34 
Doses 2 and 3 Cmins Dose 2 Cmax and Cmin 1.00 
Dose 1 Cmax and Cmin Dose 2 Cmax and Cmin 1.00 
Table 5.1: Results of the pairwise McNemar-tests of P20 by limited sampling strategy for the non-obese individuals in the ChCh 




Appendix 5.6: Multilinear regression model 
Appendix 5.6.1: Model diagnostics 
Figure 5.8 depicts the model diagnostics for the multilinear regression model. Overall, the model 
doesn’t appear to significantly deviate from assumptions of normality or homoscedasticity. 
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